

References

CHAPTER 1: IS TESTOSTERONE A MAJOR PLAYER IN THE MANAGEMENT OF DIABETES?

Testosterone is a major player in the management of diabetes

1. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S. et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men with Type 2 Diabetes. *Diabetes Care*. 2016; 39(1): 82-91.
2. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol*. 2013; 169(6):725-33.
3. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). *Int J Clin Pract*. 2014; 68(2):203-15.
4. Hackett G. Type 2 Diabetes and Testosterone Therapy. *World J Mens Health*. 2019; 37(1):31-44.
5. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction and

stroke in men with low testosterone levels. *JAMA*. 2013; 310:1829-1836.

6. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. *PLoS One*. 2014;9(1):e85805.
7. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Wittert, Gary et al. *The Lancet Diabetes & Endocrinology*, Volume 9, Issue 1, 32 - 45.

Testosterone is not a major player in the management of Type 2 diabetes

1. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic Hypogonadism in Men With Diabetes. *Diabetes Care*. 2018; 41:1516-1525.
2. Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. *J Endocrinol*. 2014; 220(3):R37-55.
3. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018; 103(5):1715-1744.

CHAPTER 2: SHOULD HBA1C STILL BE THE MAIN TARGET FOR DIABETES TREATMENT?

HbA1c is the main target for treatment of diabetes treatment

1. Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. *World J Diabetes*. 2019; 10(1):1-15.
2. Rahbar S. An abnormal hemoglobin in red cells of diabetics. *Clin Chim Acta*. 1968; 22(2):296-98.
3. Diabetes Control and Complications Trial Research Group, Nathan DM, et al. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *N Engl J Med*. 1993; 329(14):977-86.
4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998; 352(9131):854-65.
5. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. *Diabetes Care*. 2018; 41(Suppl 1):S13-S27.

HbA1c is not the main target for treatment of diabetes treatment

1. Sacks DB. Measurement of Hemoglobin A1c. *Diabetes Care*. 2012; 35:2674-680.
2. Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. *Clin Chem*. 2011; 57(2):205-14.

3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010; 33(Suppl. 1):S62-S69.
4. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of hemoglobin A1c: slow glycosylation of hemoglobin in vivo. *J Clin Invest*. 1976; 57:1652-659.
5. Gillett MJ. International Expert Committee International Expert Committee report on the role of A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009; 32:1327-1334. *Clin Biochem Rev*. 2009; 30(4):197-200.
6. Nitin S. HbA1c and factors other than diabetes mellitus affecting it. *Singap Med J*. 2010; 51:616-22.
7. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. *J Gen Intern Med*. 2014; 29(2):388-94.
8. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: Implications for the diagnosis of diabetes. *J Clin Endocrinol Metab*. 2012; 97(4):1067-072.
9. Al-Ansary L, Farmer A, Hirst J, Roberts N, Glasziou P, Perera R, et al. Point-of-care testing for HbA1c in the management of diabetes: a systematic review and metaanalysis. *Clin Chem*. 2011; 57(4):568-76.
10. Akasaka T, Sueta D, Tabata N, Takashio S, Yamamoto E, Izumiya Y, et al. Effects of the mean amplitude of glycemic excursions and vascular endothelial dysfunction on cardiovascular events in nondiabetic patients with coronary artery disease. *J Am Heart Assoc*. 2017; 6(5): pii: e004841.

11. Sun J, Dou JT, Wang XL, Yang GQ, Lü ZH, Zheng H, et al. Correlation between 1, 5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. *Chin Med J (Engl)*. 2011; 124(22):3641-645.
12. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. *Endocr J*. 2008; 55(3):503-07.
13. Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson DM, et al. The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitol, and continuous glucose monitoring. *Pediatr Diabetes*. 2011; 12(8):690-95.

CHAPTER 3: DO WE NEED BGM IN THE ERA OF CGM/FGM?

We Need BGM in the era of CGM/FGM

1. Kesavadev J, Ramachandran L, Krishnan G. Glucose monitoring technologies - complementary or competitive? Role of continuous glucose monitoring versus flash glucose monitoring versus self-monitoring of blood glucose. *J Diabetol*. 2017; 8:61-67.
2. Joubert M, Reznik Y. Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use. *Diabetes Res Clin Pract*. 2012; 96(3):294-305.
3. Siegmund T, Heinemann L, Kolassa R, Thomas A. Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target. *J Diabetes Sci Technol*. 2017; 11(4):766-72.
4. Cengiz & Tamborlane W.V .Diabetes Technology & Therapeutics 2009.
5. Mensh, Wisinslewski, Neil, Burnett Diabetes Technology & Therapeutic. In press.
6. Baquette BW. *Jrnl Dia Sci Tech*. 2011; 4(2):404-418.
7. Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. *Diabetes Res Clin Pract*. 2010;87:348-353.
8. Mazze RS, Strock E, Borgman S, Wesley D, Stout P, Racchini J. Evaluating the Accuracy, Reliability, and Clinical Applicability of Continuous Glucose Monitoring (CGM): Is CGM Ready for Real Time? *Diabetes Technol Ther*. 2009; 11:11-18.
9. Weinstein et al, *Diabetes Care* 2007
10. Kamath A, Mahalingam A, Brauker J. Analysis of Time Lags and Other Sources of Error of the DexCom SEVEN Continuous Glucose Monitor. *Diabetes Technol Ther*. 2009; 11(11):689-95.
11. Kamath A, Mahalingam A, Brauker J. Analysis of time lags and other sources of error of the DexCom SEVEN continuous glucose monitor. *Diabetes Technol Ther* 2009; 11(11):689-95.
12. Langendam M, Luijf YM, Hoof L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. *Cochrane Database Syst Rev*. 2012; 1:CD008101.

We do not need blood glucose monitoring in the era of continuous glucose monitoring or flash glucose monitoring.

1. Hoss U, Budiman ES. Factory-Calibrated Continuous Glucose Sensors: The Science Behind the Technology. *Diabetes Technol Ther.* 2017; 19(S2):S44-S50.
2. Jafri RZ, Balliro CA, El-Khatib F, Maheno M, Hillard MA, O' donovan AJ, et al. A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense CGM Devices in an Outpatient Study of Subjects with Type 1 Diabetes. *Diabetes.* 2018; 67(Supplement 1).
3. Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. *Diabetes Technol Ther.* 2018; 20(6):395-402.
4. Ekhlaspour L, Mondesir D, Lautsch N, Balliro C, Hillard M, Magyar K, et al. Comparative Accuracy of 17 Point-of-Care Glucose Meters. *J Diabetes Sci Technol.* 2017; 11(3):558-566.
5. Commissioner of the FDA expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions. FDA. 2019. Available from: <https://www.fda.gov/news-events/press-announcements/fda-expands-indication-continuous-glucose-monitoring-system-first-replace-fingerstick-testing>.
6. Heinemann L, Stuhr A, Brown A, Freckmann G, Breton MD, Russell S, et al. Self-measurement of Blood Glucose and Continuous Glucose Monitoring - Is There Only One Future? *Eur Endocrinol.* 2018; 14(2):24-29.
7. Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, et al. REPLACE-BG : A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. *Diabetes Care.* 2017; 40(4):538-545.
8. Lang J, Jangam S, Dunn T, Hayter G. 972-P: Expanded Real-World Use Reaffirms Strong Correlation between Scanning Frequency of Flash Glucose Monitoring and Glucose Control. *Diabetes.* 2019; 68(Supplement 1).
9. Al Hayek AA, Robert AA, Al Dawish MA. Evaluation of FreeStyle Libre Flash Glucose Monitoring System on Glycemic Control, Health-Related Quality of Life, and Fear of Hypoglycemia in Patients with Type 1 Diabetes. *Clin Med Insights Endocrinol Diabetes.* 2017; 10:1179551417746957.
10. Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: Clinical implications. *Indian J Endocrinol Metab.* 2013; 17(4):611-19.
11. Rama Chandran S, Tay WL, Lye WK, Lim LL, Ratnasingam J, Tan ATB, et al. Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycaemia in type 1 and type 2 Diabetes. *Diabetes Technol Ther.* 2018; 20(5):353-62.
12. Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in

Type 2 Diabetes. *Diabetes Care*. 2018; 41(11):2370-376.

13. Bolinder J, Antuna R, Geelhoed-duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes : a multicentre, non-masked, randomised controlled trial. *Lancet*. 2016; 388(10057):2254-2263.
14. ENDOCRINE TODAY 2018 J. In new era of diabetes tech, advancements poised to change management for type 1 and type 2. Available from: <https://www.healio.com/endocrinology/diabetes/news/online/%7B5d8017c5-4312-4873-a738-d176174c0014%7D/recent-diabetes-technology-updates>.

Non-Invasive Glucose Monitoring: Is the evolution complete?

1. Dicembrini I, Mannucci E, Monami M, Pala L. Impact of Technology on Glycemic Control in Type 2 Diabetes: A Meta-Analysis of Randomized Trials on Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion. *Diabetes Obes Metab*. 2019;21(12): 2619-625.
2. Blum A. Freestyle Libre Glucose Monitoring System. *Clin Diabetes*. 2018; 36(2):203-04.
3. Klonoff DC, Parkes JL, Kovatchev BP, Kerr D, Bevier WC, Brazg RL, et al. Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors. *Diabetes Care*. 2018; 41(8):1681-688.

CHAPTER 4: IS LDL STILL THE BEST LIPID PREDICTOR FOR CARDIOVASCULAR EVENT?

LDL is still the best lipid predictor for cardiovascular event

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998; 339:229-34.
2. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. *J Lipids*. 2015; 2015:971453.
3. Tohidi M, Hatami M, Hadaegh F, Safarkhani M, Harati H, Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population-based cohort study. *Lipids Health Dis*. 2010; 9:6.

LDL is not the best predictor of CV risk

1. ACC & AHA 2013 Prevention guidelines ASCVD risk estimator. Available from: <http://www.acc.org/tools-and-practice-support/mobile-resources/features/2013-prevention-guidelines-ascvd-risk-estimator>.
2. Cholesterol Treatment Trialists' Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012; 380(9841):581-90.

3. Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, et al. European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) *Eur J Prev Cardiol.* 2016; 23(11):NP1-NP96.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) *JAMA.* 2001; 285(19):2486-497.
5. Erhardt LR, Gotto A. The evolution of European guidelines: changing the management of cholesterol levels. *Atherosclerosis.* 2006; 185(1):12-20.
6. Waters DD, Boekholdt SM. An evidence-based guide to cholesterol-lowering guidelines. *Can J Cardiol.* 2016; 33(3):343-49.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996; 335(14):1001-009.
8. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2016;316(19):2008-024.
9. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet.* 2012; 380(9841):565-71.
10. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet.* 2003; 361(9364):1149-158.
11. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. *BMJ.* 2013; 346:f2610.
12. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004; 350(15):1495-504.
13. Treating to New Targets Steering Committee and Investigators, LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT]

- study). *Am J Cardiol.* 2007; 100(5):747-52.
14. Cholesterol Treatment Trialists' Collaborators. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010; 376(9753):1670-681.
 15. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015; 372(25):2387-397.
 16. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) *Circulation.* 1998; 97(15):1453-460.
 17. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol.* 2014; 64(5):485-94.
 18. Hofer TP, Hayward RA. New studies do not challenge the American College of Cardiology/American Heart Association Lipid Guidelines. *Ann Intern Med.* 2016; 165(11):827-828.
 19. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J.* 2003;24(11):987-1003.
 20. Vartiainen E, Laatikainen T, Peltonen M, Puska P. Predicting coronary heart disease and stroke: the FINRISK Calculator. *Glob Heart.* 2016; 11(2):213-16.
 21. American College of Cardiology and American Heart Association. 2013 Prevention guidelines ASCVD risk estimator. 2014 Available from: <http://www.acc.org/tools-and-practice-support/mobile-resources/features/2013-prevention-guidelines-ascvd-risk-estimator>.
 22. Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. *JAMA.* 2014; 311(14):1416-423.
 23. van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FL. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. *Eur Heart J.* 2014; 35(13):837-43.
 24. Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, et al. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. *Circulation.* 2013; 127(25):2485-493.
 25. Stam-Slob MC, Visseren FL, Wouter Jukema J, van der Graaf Y, Poulter NR, Gupta A, et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. *Clin Res Cardiol.* 2017; 106(1):58-68.

Is LDL still the best lipid predictor for cardiovascular event?

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet*. 2004; 364:937-52.
2. Chandra KS, Bansal M, Nair T, Iyengar SS, Gupta R, Manchanda SC, et al. Consensus statement on management of dyslipidemia in Indian subjects. *Indian Heart J*. 2014; 66 (Suppl 3):S1-51.
3. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: Systematic analysis of health examination surveys and epidemiological studies with 321 countryyears and 3.0 million participants. *Lancet*. 2011; 377:578-86.
4. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. *Lancet*. 2011; 377:529-32.
5. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: A review. *J Clin Epidemiol*. 1989; 42:597-609.
6. Enas EA. Coronary artery disease epidemic in Indians: A cause for alarm and call for action. *J Indian Med Assoc*. 2000; 98:694-695, 697-702.
7. Enas EA, Dharmarajan TS, Varkey B. Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective. *Indian Heart J*. 2015; 67:95-102.
8. Grundy SM. Atherogenic dyslipidemia: Lipoprotein abnormalities and implications for therapy. *Am J Cardiol*. 1995; 75:45B-52B.
9. Superko HR, Enas EA, Kotha P, Bhat NK, Garrett B. Highdensity lipoprotein subclass distribution in individuals of Asian Indian descent: The national Asian Indian heart disease project. *Prev Cardiol*. 2005 ; 8:81-6.
10. Guptha S, Gupta R, Deedwania P, Bhansali A, Maheshwari A, Gupta A, et al. Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. *Indian Heart J*. 2014; 66:280-88.
11. Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of dyslipidemia in urban and rural India: The ICMR-INDIAB study. *PLoS One*. 2014; 9:e96808.
12. Puri S, Puri S, Rehan HS, et al. Prevalence and pattern of dyslipidemia in 2500 adolescents in suburban india (abstract). *J Am Coll Cardiol*. 2015; 65:A1486.
13. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the INTERHEART study. *J Am Coll Cardiol*. 2009; 53:244-53.
14. Gupta R, Guptha S, Agrawal A, Kaul V, Gaur K, Gupta VP. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipidemias in an urban Indian population. *Lipids Health Dis*. 2008; 7:40.
15. Gupta R, Guptha S, Gupta VP, Agrawal A, Gaur K, Deedwania PC. Twenty-year

- trends in cardiovascular risk factors in India and influence of educational status. *Eur J Prev Cardiol.* 2012; 19:1258-271.
16. Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. *Lancet.* 2012; 380:581-90.
 17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation.* 2002; 106:3143-421.
 18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. *Circulation.* 2004; 110:227-39.
 19. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin). *J Am Coll Cardiol.* 2011; 57:1666-675.
 20. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015; 372:2387-397.
 21. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarencio P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. *J Am Coll Cardiol.* 2014; 64:485-94.
 22. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med.* 2006; 354:1264-272.
 23. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med.* 2015; 372:1489-499.
 24. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. *JAMA.* 2006; 295:1556-565.
 25. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif J-C, Brener SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: A study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. *Circulation.* 2008; 117:2458-466.

CHAPTER 5: SHOULD WE CONSIDER METABOLIC SURGERY FOR DIABETES OF SHORTER DURATION?

We Should Not Consider Metabolic Surgery For Diabetes of Shorter Duration

1. The Diabetes Prevention Program Research Group, Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002; 346:393-403.
2. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia.* 2006; 49(2):289-97.
3. Hamdy O, Mottalib A, Morsi A, El-Sayed N, Goebel-Fabbri A, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. *BMJ Open Diabetes Research and Care* 2017;5:e000259.
4. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet.* 2018; 10:541-51.
5. DeFronzo RA, Banerji M, Bray GA, Buchanan TA, Clement S, Henry RR, et al. Actos Now for the prevention of diabetes (ACT NOW) study. *BMC Endocr Disord.* 2009; 29:9:17.

6. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med.* 2012; 367(4):319-28.
7. Shah A, Laferrère B. Diabetes after Bariatric Surgery. *Can J Diabetes.* 2017; 41(4):401-06.

Should We Consider Metabolic Surgery for Diabetes of Shorter Duration?

1. Rachlin E, Galvani C. Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View. *Curr Diab Rep.* 2018;18(11):113. Published 2018 Sep 26. doi:10.1007/s11892-018-1094-1
2. Schauer PR, Nor Hanipah Z, Rubino F. Metabolic surgery for treating type 2 diabetes mellitus: Now supported by the world's leading diabetes organizations. *Cleve Clin J Med.* 2017;84(7 Suppl 1):S47-S56. doi:10.3949/ccjm.84.s1.06
3. Neff KJ, Le Roux CW. The Effect of Metabolic Surgery on the Complications of Diabetes: What Are the Unanswered Questions?. *Front Endocrinol (Lausanne).* 2020;11:304. Published 2020 May 29. doi:10.3389/fendo.2020.00304
4. Rubino F, Nathan DM, Eckel RH, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Surg Obes Relat Dis.* 2016;12(6):1144-1162. doi:10.1016/j.soard.2016.05.018
5. Koliaki C, Liatis S, le Roux CW, Kokkinos A. The role of bariatric surgery to treat diabetes: current challenges and perspectives. *BMC Endocr Disord.* 2017;17(1):50.

- Published 2017 Aug 10. doi:10.1186/s12902-017-0202-6
6. Bhattacharya S, Kalra S, Kapoor N, et al. Expert opinion on the preoperative medical optimization of adults with diabetes undergoing metabolic surgery. *World J Diabetes*. 2021;12(10):1587-1621. doi:10.4239/wjd.v12.i10.1587
 7. Amouyal C, Andreelli F. What is the evidence for metabolic surgery for type 2 diabetes? A critical perspective. *Diabetes Metab*. 2017;43(1):9-17. doi:10.1016/j.diabet.2016.06.005
 8. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. *Ann Surg*. 1995;222(3):339-352. doi:10.1097/0000658-199509000-00011
4. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999-2008. *J Diabetes*. 2011; 3:337-47.
 5. Ali MK, McKeever BK, Imperatore G, Barker L, Gregg EW; Centers for Disease Control and Prevention (CDC). Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes—National Health and Nutrition Examination Survey, United States, 2007-2010. *MMWR Suppl*. 2012; 61(2):32-7.
 6. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. *Diabetes Care*. 2009; 32:2225-229.
 7. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). *Circulation*. 2007; 116:151-57.
 8. Zhang Y, Hu G, Yuan Z, Chen L. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. *PLoS One*. 2012; 7:e42551.
 9. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA*. 2002; 287:2570-581.

CHAPTER 6: SHOULD WE TURN TO NEW THERAPIES IN DIABETES DESPITE THE COST?

We should turn to new therapies in diabetes despite the cost

1. American Diabetes Association. Standards of medical care in diabetes *Diabetes Care*. 2005; 28:S4-S36.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. *N Engl J Med*. 1993; 329:977-86.
3. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conven-

10. Buse JB, Ginsberg HN, Bakris GL, et al; for the American Heart Association and the American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2007; 115:114-26.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000; 321:405-12.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998; 352:837-853. Erratum in: *Lancet*. 1999; 354:602.
13. Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. *J Manag Care Pharm*. 2010; 16:264-75.
14. Van Genugten RE, Möller-Goede DL, van Raalte DH, Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. *Diabetes Obes Metab*. 2013; 15:593-606.
15. Gandra SR, Lawrence LW, Parasuraman BM, et al. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. *J Manag Care Pharm*. 2006; 12: 546-54.
16. Barnett AH, Craddock S, Fisher M, Hall G, Hughes E, Middleton A. Key consideration around the risks and consequences of hypoglycemia in people with type 2 diabetes. *Int J Clin Pract*. 2010; 64(8):1121-129.
17. Greco D, Angileri G. Drug-induced severe hypoglycemia in type 2 diabetic patients aged 80 years or older. *Diabetes Nutr Metab*. 2004; 17(1):23-26.
18. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med*. 2011; 365(21):2002-012.
19. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. *Value Health*. 2006; 9(3):193-98.
20. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycemia in insulin treated type 2 diabetes: frequency, symptoms and impaired awareness. *Diabet Med*. 2003; 20(12):1016-012.
21. Frier BM. How hypoglycemia can affect the life of a person with diabetes. *Diabetes Metab Res Rev*. 2008; 24(2):87-92.
22. Quilliam BJ, Simeone JC, Ozbay AB, Kocut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. *Am J Manag Care*. 2011; 17(10):673-80.
23. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. *Value Health*. 2011; 14(5):665-671.

24. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. *Lancet*. 2013; 382:158-69.
25. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin converting enzyme inhibitors. *Ann Intern Med*. 1999; 131:660-67.
26. Rosen AB, Hamel MB, Weinstein MC, et al. Cost-effectiveness of full medicare coverage of angiotensin converting enzyme inhibitors for beneficiaries with diabetes. *Ann Intern Med* 2005; 143:89-99.
27. Adarkwah CC, Gandjour A. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. *Int J Technol Assess Health Care*. 2010; 26:62-70.
28. Zheng T, Baskota A, Gao Y, et al. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. *Nephrol Dial Transplant*. 2015; 30: 460-66.
29. Liu ZH. Nephrology in china. *Nat Rev Nephrol*. 2013; 9:523-28.
30. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. *JAMA*. 2016; 316:1093-103.
31. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. *Diabetes Care*. 2001; 24:51-5.
32. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. *JAMA*. 2001; 285:182-89.
33. Shetty SS, Secnik K, Oglesby AK. Relationship of glycaemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. *J Manag Care Pharm*. 2005; 11(7):559-64.
34. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. *Diabetes Care*. 2005; 28:59-64.
35. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycaemic control: a longitudinal analysis [abstract]. *Value Health*. 2005; 8:356.
36. Rosenzweig JL, Weinger K, Poirier-Solomon L, Rushton M. Use of a disease severity index for evaluation of health care costs and management of comorbidities of patients with diabetes mellitus. *Am J Manag Care*. 2002; 8:950-58.
37. Steffens B. Cost-effective management of type 2 diabetes: providing quality care in a cost-constrained environment. *Am J Manag Care*. 2000; 6:(suppl 13) S697-S703.
38. Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, Harris R. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease

- management program among patients fulfilling health employer data and information set criteria. *Diabetes Care*. 2002; 25:684-89.
39. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycaemic control. *Diabetes Care*. 1997; 20:1847-53.
 40. Lynne D. Diabetes disease management in managed care organizations. *Dis Manag*. 2004; 7:47-60.

We should not turn to new therapies in diabetes despite the cost

1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract*. 2018; 138:271-81.
2. Joshi SR. Diabetes Care in India. *Ann Glob Health*. 2015; 81(6):830-38.
3. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009; 58(4):773-95.
4. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018; 41(12):2669-701.
5. New drugs for type 2 diabetes: second-line therapy – science report. CADTH Therapeutic Review, No. 4.1b. Ottawa: CADTH; 2017 Sep.
6. Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Co-transporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. *J Am Heart Assoc*. 2018; 7:e007165.
7. Wittbrodt ET, Eudicone JM, Bell KF, et al. Eligibility Varies Among the 4 Sodium–Glucose Cotransporter-2 Inhibitor Cardiovascular Trials: Implications for the General Type 2 Diabetes US Population. *Am J Manag Care*. 2018; 24(8 Suppl):S138-S145.
8. Pintat S, Fenici P, Hammar N, et al. Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study. *BMJ Open Diab Res Care*. 2019; 7:e000627.
9. Kapur A. Economic analysis of diabetes care. *Indian J Med Res*. 2007; 125:473-82.
10. Kapur A. Cost of diabetes in India. The CODI study paper presented at the Novo Nordisk. In: Kapur A, Joshi JK, eds. *Diabetes Update Proceedings*. Bangalore: Communication Workshop (P); 2000:71-7.
11. Fernandes SD, Fernandes SDA. Economic burden of diabetes mellitus and its socio-economic impact on household expenditure in an urban slum area. *Int J Res Med Sci*. 2017; 5(5):1808-813.
12. Cohen RA, Cha AE. Strategies Used by Adults With Diagnosed Diabetes to Reduce Their Prescription Drug Costs, 2017–2018. *NCHS Data Brief*. 2019; 349:1-8.

CHAPTER 7: SHOULD WE REDUCE WEIGHT IN ELDERLY TYPE 2 DIABETICS?

1. Mordarska K, Godziewska-Zawada M. Diabetes in the elderly. *Prz Menopauzalny*. 2017; 16(2): 38-43.
2. Tsigos C. Obesity in the elderly diabetic patient: is weight loss beneficial? *Diabetes Care*. 2009; 32 Suppl 2:S403-09.
3. Kalra S, Sharma SK. Diabetes in the Elderly. *Diabetes Ther*. 2018;9(2):493-500.
4. Coker RH, Wolfe RR. Weight Loss Strategies in the Elderly: A Clinical Conundrum. *Obesity (Silver Spring)*. 2018; 26(1):22-28.
5. Cheng V, Kashyap SR. Weight considerations in pharmacotherapy for type 2 diabetes. *J Obes*. 2011;2011. pii: 984245.
6. Brunton S. GLP-1 agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? *Int J Clin Pract*. 2014;68(5):557-67.

Weight Should Not be Reduced in the Elderly Type 2 Diabetics?

1. Brunton S. GLP-1 agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? *Int J Clin Pract*. 2014; 68(5):557-67.
2. Cheng V, Kashyap SR. Weight considerations in pharmacotherapy for type 2 diabetes. *J Obes*. 2011; 2011:984245.
3. Coker RH, Wolfe RR. Weight Loss Strategies in the Elderly: A Clinical Conundrum. *Obesity (Silver Spring)*. 2018; 26(1):22-8.
4. Kalra S, Sharma SK. Diabetes in the Elderly. *Diabetes Ther*. 2019; 9(2):493-500.

5. Mordarska K, Godziewska-Zawada M. Diabetes in the elderly. *Prz Menopauzalny*. 2017; 16(2): 38-43.
6. Kyrrou I, Tsigos C. Obesity in the elderly diabetic patient: is weight loss beneficial? No. *Diabetes Care*. 2009; 32 Suppl 2:S403-09.

Should We Reduce Weight in Elderly Diabetics?

1. National Institute of Diabetes and Digestive and Kidney Diseases. *Diabetes in America*, 3rd edition, 2018. Accessed date- 27/08/2019. Available online at <https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/diabetes-in-america-3rd-edition>.
2. Meneilly GS, Tessier D. Diabetes in elderly adults. *J Gerontol A: Biol Sci Med Sci* 2001; 56:M5-13.
3. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. *Am J Clin Nutr*. 2010; 91:1123S-1127S.
4. Vischer UM, Safar ME, Safar H, Iaria P, Dudal KL, Henry O, et al. Cardiometabolic determinants of mortality in a geriatric population: is there a "reverse metabolic syndrome"? *Diabetes Metab*. 2009; 35:108-14.
5. Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. *Ann Intern Med*. 2008; 149:11-19.
6. Stewart KJ. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mech-

- anisms for improving cardiovascular health. *JAMA*. 2002; 288:1622–631.
7. Diabetes Prevention Program Research Group; Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HF, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009; 374:1677–686.
 8. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, et al.; Look AHEAD Research Group. Lifestyle change and mobility in obese adults with type 2 diabetes. *N Engl J Med*. 2012; 366:1209–217.
 9. Arterburn DE, Crane PK, Sullivan SD. The coming epidemic of obesity in elderly Americans. *J Am Geriatr Soc*. 2004;52:1907–912.
 10. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? *Am J Epidemiol*. 1996; 143:228–39.
 11. Zamboni M, Armellini F, Harris T, Turcato E, Micciolo R, Bergamo-Andreis IA, et al. Effects of age on body fat distribution and cardiovascular risk factors in women. *Am J Clin Nutr*. 1997; 66: 111–15.
 12. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001; 344:1343–350.
 13. Kyrrou I, Tsigos C. Obesity in the Elderly Diabetic Patient Is weight loss beneficial? *No. Diabetes Care*. 2009; 32 Suppl 2(Suppl 2):S403-09.
 14. Busetto L, Angrisani L, Basso N, Favretti F, Furbetta F, Lorenzo M, Italian Group for Lap-Band. Safety and efficacy of laparoscopic adjustable gastric banding in the elderly. *Obesity (Silver Spring)* 2008; 16:334–38.

CHAPTER 8: EARLY COMBINATION VS. STEPWISE THERAPY IN TYPE 2 DIABETES MELLITUS

A Step-By-Step Strategy to Managing Type 2 Diabetes

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, vol. 2000, 2002.
2. Harris MI. Diabetes in America: epidemiology and scope of the problem. *Diabetes Care*. 1998; 21 Suppl 3:C11-4.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care*. 1998; 21(9):1414–31.
4. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. *Endocr Rev*. 1998; 19(4):477-90.
5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized

- prospective 6-year study. *Diabetes Res Clin Pract.* 1995; 28(2):103-17.
6. Diabetes Control and Complications Research Group; D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993; 329(14):977-86.
 7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998; 352(9131):837-53.
 8. American College of Endocrinology. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. *Endocr Pract.* 2002; 8 (Suppl. 1) :5-11.
 9. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care.* 2003; 26 Suppl 1:S33-50.
 10. Diabetes Canada Clinical Practice Guidelines Expert Committee. Nutrition Therapy: Canadian Diabetes Association Clinical Guidelines Expert Committee, 2003. Online available at: <http://www.diabetes.ca/cpg2003/downloads/nutrition.pdf>.
 11. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. *Diabetes.* 1995; 44(11):1249-58.
 12. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson J-L, Garg A, American Diabetes Association, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care.* 2003; 26 Suppl 1:S51-61.
 13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002; 346(6):393-403.
 14. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. *JAMA.* 2002; 287(3):360-72.
 15. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, et al. National standards for diabetes self-management education, Task Force to Review and Revise the National Standards for Diabetes Self-Management Education Programs. *Diabetes Care.* 2000; 23(5):682-89.
 16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet.* 1998; 352(9131):854-65.
 17. Perfetti R, Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. *Trends Endocrinol Metab.* 2000; 11(6):218-23.
 18. Levien T, Baker DE, Campbell RK, White JR. Nateglinide therapy for type 2 diabetes. *Ann Pharmacother.* 2001; 35(11):1426-34.
 19. Parulkar AA, Pendergrass M, Granda-Ayala R, Lee T, Fonseca V. Non-hypoglycemic

- effects of thiazolidinediones. *Ann Intern Med.* 2001; 134(1):61-71.
20. Horton E, Whitehouse F, Ghazzi MN, Venable T, Whitcomb RW, The Troglitazone Study Group. Troglitazone in combination with sulfonylureas restores glycemic control in patients with type 2 diabetes. *Diabetes Care.* 1998; 21(9):1462-469.
 21. Barnett AH. Insulin-sensitizing agents—thiazolidinediones (glitazones). *Curr Med Res Opin.* 2002;18 Suppl 1:s31-9.
 22. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution in patients with type 2 diabetes. *Diabetes Care.* 1999; 22(2):288-93.
 23. Murphy EJ, Davern TJ, Shakil AO, Shick L, Masharani U, Chow H, et al. Acute Liver Failure Study Group. Troglitazone-induced fulminant hepatic failure. *Dig Dis Sci.* 2000; 45(3):549-53.
 24. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. *Diabet Med.* 2000; 17(1):40-7.
 25. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL, The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. *Clin Ther.* 2000; 22(12):1395-409.
 26. Fonseca V, Rosenstock J, Patwardhan RN, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. *JAMA.* 2000; 283(13):1695-702.
 27. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D, Glyburide/Metformin Initial Therapy Study Group.
 28. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. *Diabetes Obes Metab.* 2002;4(3):201-08.
 29. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* . 2001; 134(9 Pt 1):737-45.
 30. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P, INS-2061 Study Team
 31. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. *BMJ.* 1997; 314(7093):1512-5.
 32. Malmberg K, DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ.* 1997; 314(7093):1512-525.
 33. Riddle MC. The underuse of insulin therapy in North America. *Diabetes Metab Res Rev.* 2002; 18 Suppl 3:S42-9.
 34. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment

- reverses the insulin resistance of type II diabetes mellitus. *Diabetes Care*. 1982; 5(4):353-63.
35. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. *Diabetes*. 1984; 33(7):634-42.
 36. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. *Diabetes*. 1985; 34(3):222-34.
 37. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with non-insulin-dependent diabetes. *Diabetologia*. 1999; 42(4):406-12.
 38. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes. *Diabetes Care*. 2001; 24(10):1849-850.
 39. Rosenstock J, Schwartz SL, Clark Jr. CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. *Diabetes Care*. 2001; 24(4):631-36.
 40. Fritsche A, Schweitzer MA, Haring H-U, The 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. *Ann Intern Med*. 2003; 138(12):952-59.
 41. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care*. 2003; 26(11):3080-086.
 42. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes: a meta-analysis of the randomized placebo-controlled trials. *Arch Intern Med*. 1996; 156(3):259-64.
 43. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. *Diabetes Care*. 2001; 24(4):758-67.
 44. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. *Diabetes*. 1999; 48(12):2414-421.
 45. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. *Diabetes*. 2002; 51(3):724-33.
 46. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. *Diabet Med*. 1993;10(3):231-37.

Early Intensification of Insulin in Type 2 Diabetes Mellitus

1. Fonseca VA. Defining and characterizing the progression of type 2 Diabetes. *Diabetes Care*. 2009; 32(Suppl.):S151-S56.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 Diabetes, 2015: a patient-centred ap-

- proach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*. 2015; 58:429–42.
3. Control Group; Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 Diabetes. *Diabetologia*. 2009; 52:2288–298.
 4. Shah S, Sharma SK, Singh P, Muruganathan A, Das AK, Diabetes Consensus Group. Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus. *J Assoc Physicians India*. 2014; 62(7 Suppl):49–54.
 5. Kumar A, Kesavadev J, Sethi B, Jain SM, Guruprasad CS, Shah SN. Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges. *J Assoc Physicians India*. 2015; 63(5 Suppl):8–14.
 6. Wangnoo SK, Damodharan S, Sastry NG, Bhattacharyya S, Selvan C, Mohan B, et al. Intensification of Gla-100 with Prandial Insulin: A Stepwise Progression Toward Glycemic Control. *J Assoc Physicians India*. 2020; 68(12[Special]):43–48.
 7. Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, et al. EADSG Guidelines: Insulin Therapy in Diabetes. *Diabetes Ther*. 2018; 9:449–92.
 8. Hanefeld M, Fleischmann H, Siegmund T, Seufert J. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. *Diabetes Ther*. 2020; **11**: 1645–666.
 9. Aziz MSA, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. *Diabetes Obes Metab*. 2017; 19(2):216–27.
 10. Avogaro A, Delgado E, Lingvay I. When metformin is not enough: pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. *Diabetes Metab Res Rev*. 2018; 34(4):e2981.
 11. Monami M, Liistro F, Scatena A, Nreu B, Mannucci E. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2018; 20(5):1213–22.
 12. Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. *Diabetes Care*. 2008; 31(10):1927–932.
 13. ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012; 367(4):319–28.
 14. Owens DR. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. *Diabetes Technol Ther*. 2013; 15(9):776–85.
 15. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, et al. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis

- model assessment. *Diabet Med.* 1988; 5:36–41.
16. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. *Diabetes.* 1995; 44(11):1249-258. Erratum in: *Diabetes* 1996; 45(11):1655.
 17. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B, Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycemic goal. *Int J Clin Pract.* 2005; 59(11):1345-355.
 18. Thacker H. 1588-P: Therapy Trends in Initial 6 Months of the First Large-Scale Longitudinal Nationwide Study on Management and Real-World Outcomes of Diabetes in India (LANDMARC). Online available at: https://plan.core-apps.com/tristar_ada20/abstract/56a6eb60-8ae5-4ed9-854b-d668db861841.
 19. Mohan V, Mukherjee JJ, Das AK, Seshadri K, Dasgupta A. Initiation and intensification of insulin therapy in type 2 diabetes mellitus: Physician barriers and solutions – An Indian perspective. *Endocrine and Metabolic Science.* 2021; 4:100103.
 20. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2013;1(1):28–34.
 21. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovasc Diabetol.* 2015; 14:100.
 22. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009; 360:129–39.
 23. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. *Diabetes Care.* 2004; 27(7):1535-540.
 24. Khunti K, Millar-Jones D. Clinical inertia to insulin initiation and intensification in the UK: A focused literature review. *Prim Care Diabetes.* 2017; 11(1):3-12.
 25. Asche CV, Bode B, Busk AK, Nair SR. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2012; 14(1):47-57.
 26. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. *Diabetes Res Clin Pract.* 2007; 78:254–58.
 27. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. *J Eval Clin Pract.* 2012; 18:256–61.
 28. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. *Diabetes Metab Syndr.* 2020; 14(3):211-12.
 29. The OpenSAFELY Collaborative; Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic

health records of 17 million adult NHS patients. Online available at: <https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1.full.pdf>.

30. Khare J, Jindal S. Observational study on Effect of Lock Down due to COVID 19 on glycemic control in patients with Diabetes: Experience from Central India. *Diabetes Metab Syndr*. 2020; 14(6):1571-574.

Early Combination Vs. Stepwise Therapy in Type 2 Diabetes Mellitus

1. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021; 44(Suppl 1):S73-S84.
2. Viswanathan M, Ramachandran A, Mohan V. Low dosage combination therapy of glybenclamide and phenformin maturity-onset. *J Diabet Assoc India*. 1975; 15:145-49.
3. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009; 58(4):773-95.
4. Kumar M, Rawat R, Verma VK, Zafar KS, Kumar G. Chronic complications in newly diagnosed patients with type 2 diabetes mellitus in rural area of western Uttar Pradesh, India. *International Journal of Research in Medical Sciences*. 2016; 4(6):2291-296.
5. Ferrannini E. Sodium-glucose co-transporters and their inhibition: Clinical physiology. *Cell Metab*. 2017; 26:27-38.
6. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017; 377:644-57.
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015; 373:2117-128.
8. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019; 380(4):347-57.
9. Milder TY, Stocker SL, Abdel Shaheed C, McGrath-Cadell L, Samocho-Bonet D, Greenfield JR, et al. Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. *J Clin Med*. 2019; 8(1):45.

CHAPTER 9: LOW CARBOHYDRATE VS LOW CALORIE DIET

Low-Calorie Diet

1. Luhar S, Mallinson PAC, Clarke L, Kinra S. Trends in the socioeconomic patterning of overweight/obesity in India: a repeated cross-sectional study using nationally representative data. *BMJ Open*. 2018; 8(10):e023935.
2. Unnikrishnan AG, Kalra S, Garg MK. Preventing obesity in India: Weighing the options. *Indian J Endocrinol Metab*. 2012; 16(1):4-6.
3. Luhar S, Mallinson PAC, Clarke L, Kinra S. Do trends in the prevalence of overweight by socio-economic position differ between India's most and least economically developed states? *BMC Public Health*. 2019; 19(1):783.

4. Dinsa GD, Goryakin Y, Fumagalli E, Suhrcke M. Obesity and socioeconomic status in developing countries: A systematic review. *Obes Rev.* 2012; 13(11):1067-079.
5. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. *JRSM Cardiovasc Dis.* 2016; 5:2048004016633371.
6. Clare Grace and Adrian Brown. Dietary and Behavioural Interventions in the Management of Obesity. *Advanced Practice in Endocrinology Nursing.* 2019; 1065-1083.
7. Mahan LK, Raymond J. Krause's Food and Nutrition care process (14th edition). 2016.
8. Umphonsathien M, Prutanopajai P, Aiam-O-Ran J, Thararoop T, Karin A, Kanjanapha C, et al. Immediate and long-term effects of a very-low-calorie diet on diabetes remission and glycemic control in obese Thai patients with type 2 diabetes mellitus. *Food Sci Nutr.* 2019; 7(3):1113-1122.
4. Pamela Dyson. Low carbohydrate diets and Type 2 Diabetes: What is the latest evidence? *Diabetes Ther.* 2015; 6(4):411-24.
5. Hu T, Mills KT, Yao L, Demanelis K, Eloustaz M, Yancy WS Jr, et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. *Am J Epidemiol.* 2012; 176(suppl 7):S44-S54.
6. Kennedy ET, Bowman SA, Spence JT, Freedman M, King J. Popular diets: correlation to health, nutrition, and obesity. *J Am Diet Assoc.* 2001; 101(4):411-20.
7. Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, et al. Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. *BMJ.* 2016; 353:i2716.
8. Ma X, Tang WG, Yang Y, Zhang QL, Zheng JL, Xiang YB. Association between whole grain intake and all-cause mortality: a meta-analysis of cohort studies. *Oncotarget.* 2016; 7(38):61996-2005.

Low-Carbohydrate Diet

1. ICMR Guidelines for Management of Type 2 Diabetes 2018. <https://medibulletin.com/wp-content/uploads/2018/05/ICMR.diabetesGuidelines.2018.pdf>
2. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. *Nutrition.* 2015; 31(1):1-13.
3. Fred Brouns. Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommended?. *Eur J Nutr.* 2018; 57(4):1301-312.
9. Albertson AM, Reicks M, Joshi N, Gugger CK. Whole grain consumption trends and associations with body weight measures in the United States: results from the cross sectional National Health and Nutrition Examination Survey 2001-2012. *Nutr J.* 2016; 15:8.
10. Vanegas SM, Meydani M, Barnett JB, Goldin B, Kane A, Rasmussen H, et al. Substituting whole grains for refined grains in a 6-wk randomized trial has a modest effect on gut microbiota and immune

- and inflammatory markers of healthy adults. *Am J Clin Nutr.* 2017; 105(3):635-50.
11. Krebs JD, Elley CR, Parry-Strong A, Lunt H, Drury PL, Bell DA, et al. The diabetes excess weight loss (DEWL) trial: a randomized controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. *Diabetologia.* 2012; 55(4):905-14.
 12. Franz MJ. Protein Controversies in Diabetes. *Diabetes Spectrum.* 2000; 13(3):132.
 13. Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. *Int J Obes Relat Metab Disord.* 2004; 28(10):1283-290.
 14. Luscombe ND, Clifton PM, Noakes M, Parker B, Wittert G. Effects of energy-restricted diets containing increased protein on weight loss, resting energy expenditure, and the thermic effect of feeding in type 2 diabetes. *Diabetes Care.* 2002; 25(4):652-57.
 15. Brinkworth GD, Noakes M, Parker B, Foster P, Clifton PM. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. *Diabetologia.* 2004; 47(10):1677-686.
 16. Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. *Diabetologia.* 2011; 54:731-40.
 17. de Bock M, Lobley K, Anderson D, Davis E, Donaghue K, Pappas M, et al. Endocrine and metabolic consequences due to restrictive carbohydrate diets in children with type 1 diabetes: An illustrative case series. *Pediatr Diabetes.* 2018; 19(1):129-37.
 18. Carlton JD. Prevalence of micronutrient deficiency in popular diet plans. *J Int Soc Sports Nutr.* 2010; 7:24.
 19. Gardner CD, Kim S, Bersamin A, Doppler-Nelson M, Otten J, Oelrich B, et al. Micronutrient quality of weight-loss diets that focus on macronutrients: results from the A to Z study. *Am J Clin Nutr.* 2010; 92(2):304-12.
 20. Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. *JAMA.* 2002; 287(23):3127-129.
 21. Field CJ, Johnson IR, Schley PD. Nutrients and their role on host resistance to infection. *J Leuk Biol.* 2002; 71:16-32.
 22. Desrosiers TA, Siega-Riz AM, Mosley BS, Meyer RE; National Birth Defects Prevention Study. Low carbohydrate diets may increase risk of neural tube defects. *Birth Defects Res.* 2018; 110(11):901-09.

Low-Carbohydrate v/s Low-Calorie Diet

1. Anderson JW, Konz EC, Jenkins DJ. Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review. *J Am Coll Nutr.* 2000; 19(5):578-90.
2. Freedman MR, King J, Kennedy E. Popular diets. A scientific review. *Obes Res.* 2001; 9(Suppl 1):1S-40S.

3. Bethesda. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adult. The evidence report. *Obes Res.* 1998; 6 Suppl 2:51S-209S.
4. American Association of clinical Endocrinologists (AACE) obesity statement AACE/ ACE Position Statement on the prevention, diagnosis and treatment of obesity – very low calorie diet. *JAMA.*
5. Ebbeling CB, Feldman HA, Klein GL, Wong JMW, Bielak L, Steltz SK, et al. Effects of low carbohydrate diet. *BMJ.* 2018; 363:k4583.
6. Redman LM, Smith SR, Burton JH, Martin CK, Il'yasova D, Ravussin E. Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging. *Cell Metab.* 2018; 27(4):805-815.e4.
7. Prof. B.B.Tripathi Nutrition Symposium dietary carbohydrate consumption in diabetes Patients and Normal individuals. BBT01. *Int J Diabetes Dev Ctries (November 2018)* 38 (Suppl 2):S117–S176.
8. Hill JO, Wyatt HR. Role of Physical activity in preventing and treating obesity. *J Appl Physiol* (1985). 2005; 99(2):765-70.
- Medical Record. *J Korean Med Sci.* 2018; 33(34):e213.
3. Dal-Ré R, Janiaud P, Ioannidis JPA. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic? *BMC Med.* 2018; 16(1):49.
4. Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. *Rheumatology (Oxford).* 2018; 57(57 Suppl 7):vii54-vii58.
5. Bondemark L, Ruf S. Randomized controlled trial: the gold standard or an unobtainable fallacy? *Eur J Orthod.* 2015; 37(5):457-61.
6. MacGill M. What is a randomized controlled trial? *Medscape* [online]. Available at: <https://www.medicalnewstoday.com/articles/280574.php>. Assessed on August 21, 2019.
7. Bhatt A. Conducting real-world evidence studies in India. *Perspect Clin Res.* 2019; 10:51-56.
8. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Design and baseline characteristics of the Cardiovascular Outcome Trial of LINagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). *Diab Vasc Dis Res.* 2015; 12(3):164-74.
9. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. *Adv Ther.* 2018; 35(11):1763-774.
10. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower Risk of Heart Failure and Death

CHAPTER 10: RANDOMISED CLINICAL TRIALS VS. REAL-WORLD DATA

1. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: The role of effectiveness studies in evaluating cardiovascular therapies. *Circulation.* 2008; 118(12):1294-303.
2. Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic

- in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). *Circulation*. 2017; 136(3):249-59.
11. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. *Am Heart J*. 2014; 167(3):329-34.

Randomized Clinical Trials Versus Real-World Data/Evidences- For Rwes

1. A Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. *Br Med J*. 1948; 2(4582):769-82.
2. Glossary of terms on clinical trials for patient engagement advisory committee meeting. Online available at- <https://www.fda.gov/media/108378/download#:~:text=Randomized,to%20assign%20patients%20to%20treatments>. Accessed date- 7/08/2020.
3. Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. *J Korean Med Sci*. 2018; 33(34):e213.
4. Lee JY, Park BJ. A method to evaluate scientific evidence in clinical preventive medicine. *J Korean Med Assoc*. 2011;54(10):1006-012.
5. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. *J Clin Epidemiol*. 2009; 62:499-505.
6. Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials. *J Clin Epidemiol*. 2010; 63:1053-058.
7. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. *Circulation*. 1981; 64(4):669-73.
8. Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking. *Fam Med*. 2007; 39(2):132-37.
9. Coloma PM, Trifirò G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? *Drug Saf*. 2013; 36(3):183-97.
10. US Food and Drug administration. Real-world evidence. Online available at at <https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence>. Accessed date- 7/08/2020.
11. Gabay M. 21st Century Cures Act. *Hosp Pharm*. 2017; 52(4):264-65.
12. Tanaka S, Yamamoto T, Oda E, Nakamura M, Fujiwara S, et al. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database. *J Bone Miner Metab*. 2018; 36(1):87-94.

13. Dang A, Vallish BN. Real world evidence: An Indian perspective. *Perspect Clin Res*. 2016; 7(4):156–60.
14. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. *Nat Rev Drug Discov*. 2011; 10(7):495–506.
15. Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand S-L. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. *Value Health*. 2012; 15(2):217–30.
16. Lamberti MJ, Kubick W, Awatin J, McCormick J, Carroll J, Getz K. The use of real-world evidence and data in clinical research and postapproval safety studies. *Ther Innov Regul Sci*. 2018; 52:778–83.
17. Mentz RJ, Hernandez AF, Berdan LG, Rorick T, O'Brien EC, Ibarra JC, et al. Good clinical practice guidance and pragmatic clinical trials: Balancing the best of both worlds. *Circulation*. 2016; 133:872–80.
18. The Gazette of India. PART II—Section 3—Sub-section (i). Online available at https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf. Accessed date- 8/08/2020.
2. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC, et al. Vitamin E consumption and the risk of coronary disease in women. *N Engl J Med*. 1993; 328(20):1444–449.
3. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. *N Engl J Med*. 2000; 342(3):154–60.
4. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med*. 1996; 334(18):1150–155.
5. De Marco M, de Simone G, Izzo R, Mancusi C, Sforza A, Giudice R, et al. Classes of antihypertensive medications and blood pressure control in relation to metabolic risk factors. *J Hypertens*. 2012; 30:188–93.
6. Edelman SV, Polonsky WH. Type 2 diabetes in the real world: The elusive nature of glycemic control. *Diabetes Care*. 2017; 40(11):1425–432.
7. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M, et al. The Precise-2 tool: designing trials that are fit for purpose. *BMJ*. 2015; 350:h2147.
8. Trial of secondary prevention with atenolol after transient ischemic attack or non-disabling ischemic stroke The Dutch TIA Trial Study Group. *Stroke*. 1993; 24(4):543–48.

Randomised Controlled Trials Versus Real-World Evidence

1. A Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. *Br Med J*. 1948; 2(4582):769–82.

CHAPTER 11: IS DIABETES EQUIVALENT TO CORONARY ARTERY DISEASE?

1. Elhadd TA, Al-Amoudi AA, Alzahrani AS. Epidemiology, clinical and complications profile of diabetes in Saudi Arabia: a review. *Ann Saudi Med.* 2007; 27(4):241-50.
2. Alhabib KF, Sulaiman K, Al-Motarreb A, Almahmeed W, Asaad N, Amin H, et al. Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2). *Ann Saudi Med.* 2012; 32(1):9-18.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106(25):3143-421.
4. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation.* 1993; 88(3):837-45.
5. Himmelmann A, Hansson L, Svensson A, Harmsen P, Holmgren C, Svanborg A. Predictors of stroke in the elderly. *Acta Med Scand.* 1988; 224(5):439-43.
6. Suzuki LA, Poot M, Gerrity RG, Bornfeldt KE. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. *Diabetes.* 2001; 50(4):851-60.
7. Williams SB1, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. *J Am Coll Cardiol.* 1996; 27(3): 567-574.
8. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. *Diabetes Care.* 2001; 24(8):1476-485.
9. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. *Circulation.* 2000; 102 (18): 2180-184.
10. Marfella R, D'Amico M, Esposito K, Baldi A, Di Filippo C, Siniscalchi M, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. *Diabetes.* 2006; 55 (3): 622-32.
11. Yoo WS, Kim HJ, Kim D, Lee MY, Chung HK. Early detection of asymptomatic coronary artery disease in patients with type 2 diabetes mellitus. *Korean J Intern Med.* 2009; 24(3):183-89.
12. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. *Diabetes Care.* 2004; 27(3):813-23.
13. Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. *Cholesterol.* 2013; 792090.

14. Yan Y, Chang Q, Li Q, Li L, Wang S, Du R, et al. Identification of plasma vascular endothelia-cadherin as a biomarker for coronary artery disease in type 2 diabetes mellitus patients. *Int J Clin Exp Med*. 2015; 8(10):19466-9470.
15. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. *Diabetes Care*. 2010; 33(2):442-49.
16. Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes—a two year follow-up of 243 patients. *Cardiovasc Diabetol*. 2009; 8:48.
17. García-Fontana B, Morales-Santana S, Díaz Navarro C, Rozas-Moreno P, Geniloud O, Vicente Pérez F, et al. Metabolic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: a pilot study. *Talanta*. 2016; 148: 135-43.
18. Wang Z, Song HY, An MM, Zhu LL. Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. *Int J Clin Exp Med*. 2015; 8(10):19290-9296.
19. Palazhy S, Kamath P, Vasudevan DM. Elevated oxidative stress among coronary artery disease patients on statin therapy: a cross sectional study. *Indian Heart J*. 2015; 67:227-232.
20. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract*. 2014; 103 (2):137-49.
21. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract*. 2011; 94(3):311-21.
22. Centers for Disease Control and Prevention. Number (in Millions) of Civilian, Non- institutionalized Adults with Diagnosed Diabetes, United States, 1980-2014 (CDC website). 2015. Online available at: www.cdc.gov/diabetes/statistics/prev/national/figadults.htm. Accessed date- 3/1/2016.
23. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1998; 339(4):229-34.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA*. 2001; 285:2486-497.
25. Bulughapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. *Diabet Med*. 2009; 26:142-48.
26. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. *Arch Intern Med*. 2011; 171(5):404-10.

27. Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, et al. Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial. *Circ Cardiovasc Qual Outcomes*. 2013; 6(2):164-70.
28. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, et al. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study. *Diabetologia*. 2005; 48(12):2519-524.
29. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. *Circulation*. 2008; 117(15):1945-954.
30. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. *Arch Intern Med*. 2001; 161(14):1717-723.
31. Huang ES, Laiteerapoing N, Liu J, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older diabetes patients: the diabetes and aging study. *JAMA Intern Med*. 2014; 174(2):251-58.
32. Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. *J Gen Intern Med*. 2016; 31(4):387-93.
33. Malik S, Budoff MJ, Katz R, Blumenthal RS, Bertoni AG, Nasir K, et al. Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi ethnic study of atherosclerosis. *Diabetes Care*. 2011; 34(10):2285-290.
34. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. *J Am Coll Cardiol*. 2014; 63:2935-959.
35. Wong ND, Glovaci D, Wong K, Malik S, Franklin SS, Wygant G, et al. Global cardiovascular disease risk assessment in United States adults with diabetes. *Diab Vasc Dis Res*. 2012; 9(2):146-52.
36. Silverman MG, Blaha MJ, Budoff MJ, Rivera JJ, Raggi P, Shaw LJ, et al. Potential implications of coronary artery calcium testing for guiding aspirin use among asymptomatic individuals with diabetes. *Diabetes Care*. 2012; 35(3):624-26.
37. Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2015; 66(15):1657-668.
38. Valenti V, Hartaigh BÓ, Cho I, Schulman-Marcus J, Gransar H, Heo R, et al. Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk

- of mortality: a 15-year follow-up study of 9,715 patients. *Circ Cardiovasc Imaging*. 2016; 9(2):e003528.
39. Budoff MJ, Raggi P, Beller GA, Berman DS, Druz RS, Malik S, et al. Noninvasive cardiovascular risk assessment of the asymptomatic diabetic patient: The Imaging Council of the American College of Cardiology. *JACC Cardiovasc Imaging*. 2016; 9(2):176-92.
 40. National Institutes of Health. Precision Medicine Initiative Cohort Program: Scale and Scope (NIH website). 2016. Online available at: <https://www.nih.gov/precision-medicine-initiative-cohort-program/scale-scope>. Accessed date-3/1/2016.
- ### Is Diabetes Equivalent to Coronary Artery Disease? - No
1. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. clinical implications of UGDP results. *JAMA*. 1971; 218:1400-410.
 2. Haffner SM, Lehto S, Rönkä T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med*. 1988; 339:229-34.
 3. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. *Diabetologia*. 2013; 56(4):686-95.
 4. Diabetes Control and Complications Trial Research Group; D M Nathan, Genuth S, Lachin J, Cleary J, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993; 329:977-86.
 5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. *Lancet*. 1998; 352:837-53.
 6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988; 37:1595-607.
 7. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. *Circulation* 2000; 102:2180-184.
 8. Preiss D, Welsh P, Murray HM, Shepherd J, Packard C, Macfarlane P, et al. Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. *Eur Heart J*. 2010; 31:1230-236.
 9. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010; 375:2215-222.
 10. Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw K-T, Wareham NJ, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycosylated hemoglobin improve the prediction of coronary heart

- disease events? *Arch Intern Med.* 2008; 168:1209–216.
11. Schöttker B, Müller H, Rothenbacher D, Brenner H. Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. *Diabetologia.* 2013; 56:92–100.
 12. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. *Arch Intern Med.* 2011; 171:404–10.
 13. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. *BMJ.* 2002; 324:939–42.
 14. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes. *Diabetes Care.* 2002; 25(7):1129–134.
 15. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008; 358:2545–559.
 16. ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008; 358:2560–572.
 17. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009; 360:129–39.
 18. Yudkin JS, Richter B. Intensive glucose control and cardiovascular outcomes. *Lancet.* 2009; 374:522.
 19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med.* 2008; 358:580–91.
 20. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of causes specific death. *N Engl J Med.* 2011; 364:829–41.
 21. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, et al. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. *Diabetes Care.* 2012; 35:1252–257.

Is Diabetes Equivalent To Coronary Artery Disease?

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106:3143–421.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallon-

- geville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). *Eur J Cardiovasc Prev Rehabil.* 2003; 10:S1.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 1998; 339:229-34.
 4. Anjana RM, Unnikrishnan R, Mugilan P, Jagdish PS, Parthasarathy B, Deepa M, et al. Causes and predictors of mortality in Asian Indians with and without diabetes-10 year follow-up of the Chennai Urban Rural Epidemiology Study (CURES - 150). *PLoS One.* 2018; 13(7):e0197376.
 5. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2020; 75(5):525-58.
 6. Park GM, An H, Lee SW, Cho YR, Gil EH, Her SH, et al. Risk score model for the assessment of coronary artery disease in asymptomatic patients with type 2 diabetes. *Medicine (Baltimore).* 2015; 94(4):e508.
 7. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol.* 2018; 17(1):83.
 8. Yang JJ, Yu D, Wen W, Saito E, Rahman S, Shu X-O, et al. Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia: A Pooled Analysis of More Than 1 Million Participants. *JAMA Network Open.* 2019; 2(4):e192696.

CHAPTER 12: TIME TO CHANGE CLINICAL POSITION OF METFORMIN

Time to Change Clinical Position of Metformin: Yes

1. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. *Diabetologia.* 2017; 60(9):1620-629.
2. Ghani AM, DeFronzo RA. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. *Diabetes Care.* 2017; 40(8):1121-127.
3. Younk LM, Lamos EM, Davis SN. Cardiovascular effects of anti-diabetes drugs. *Expert Opin Drug Saf.* 2016; 15(9):1239-257.
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care.* 2002; 25(suppl 1): S1-S2.
5. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab.* 2011; 13(3):221-28.
6. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, et al. Reappraisal of metformin efficacy in the

- treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. *PLoS Med.* 2012; 9(4):e1001204.
7. Ma RC. Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes? *Lancet Diabetes Endocrinol.* 2014; 2(1):6-7.
 8. www.thelancet.com/diabetes-endocrinology Vol 2 January 2014.
 9. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2020; 41(2):255-323.
- formin-The Good Old Drug. *Pharmaceuticals (Basel).* 2021;14(2):122.
6. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. *Diabetologia.* 2017; 60(9):1586-593.
 7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care.* 2002; 25(suppl 1): S1-S2.
 8. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? *Ther Adv Endocrinol Metab.* 2021; 12:2042018820980225.

Time to Change Clinical Position of Metformin-No

1. Inzucchi SE. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. *Diabetes Care.* 2017; 40(8): 1128-132.
2. Snehalatha C, Priscilla S, Nanditha A, Arun R, Satheesh K, Ramachandran A. Metformin in Prevention of Type 2 Diabetes. *J Assoc Physicians India.* 2018; 66(3):60-63.
3. Wróbel MP, Marek B, Kajdaniuk D, Rokicka D, Szyborska-Kajane A, Strojek K. Metformin - a new old drug. *Endokrynol Pol.* 2017; 68(4):482-96.
4. Giaccari A, Solini A, Frontoni S, Del Prato S. Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism? *Diabetes Care.* 2021; 44(3):647-54.
5. Drzewoski J, Hanefeld M. The Current and Potential Therapeutic Use of Met-

Time To Change Clinical Position OF Metformin

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009; 58:773-95.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care.* 2015; 38:140-49.
3. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). Consensus statement of the American Association of Clinical Endocrinology and American College of Endocrinology

- on the comprehensive type 2 diabetes algorithm—2015 executive summary. *Endocr Pract.* 2015; 21:1403–414.
- International Diabetes Federation Clinical Guidelines Task Force. *Global Guideline for Type 2 Diabetes.* Brussels, Belgium, International Diabetes Federation. 2012; 44–46.
 - Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med.* 2006; 355:2427–443.
 - United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. *BMJ.* 1995; 310:83–8.
 - Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. *Diabetes Obes Metab.* 2015; 17:268–75.
 - Abdul-Ghani M, Mujahid O, Mujahid A, Adams J, Triplitt C, DeFronzo RA, et al. Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulphonylurea plus metformin: the QATAR Study. *Diabetes Care.* 2017; 40:325–31.
 - Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016; 375:311–22.
 - Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2016; 375:1834–844.
 - Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. *J Biomed Biotechnol.* 2010; 2010:476279.
 - Groop LC, Widén E, Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? *Diabetologia.* 1993; 36:1326–331.
 - Shalata A, Jazmawi W, Aslan O, Badarni K, Dabbah K, Sawaed S, et al. Early metabolic defects in Arab subjects with strong family history of type 2 diabetes. *J Endocrinol Invest.* 2013; 36:417–21.
 - Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. *J Clin Hypertens (Greenwich).* 2011; 13:238–43.
 - Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. *Diabetes.* 2003; 52:2461–474.

16. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet*. 2014; 383:1068–083.
17. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi E. Natural history of β -cell adaptation and failure in type 2 diabetes. *Mol Aspects Med*. 2015; 42:19–41.
18. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al. β -Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. *Diabetes Care*. 2014; 37:1751–758.
19. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. *N Engl J Med*. 1988; 319:1500–506.
20. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. β -Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. *J Clin Endocrinol Metab*. 2005; 90:493–500.
21. Ferrannini E, Mari A. β -Cell function in type 2 diabetes. *Metabolism*. 2014; 63:1217–227.
22. Polonsky KS. Lilly Lecture 1994. The β -cell in diabetes: from molecular genetics to clinical research. *Diabetes*. 1995; 44:705–17.
23. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. *Annu Rev Nutr*. 2010; 30:273–90.
24. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. *Med Clin North Am*. 2011; 95:875–92.
25. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. *Diabetologia*. 2010; 53:1270–287.
26. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. *Lancet Diabetes Endocrinol*. 2016; 4:525–36.
27. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. *Diabetes Care*. 2016; 39:884–92.
28. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. *Metabolism*. 2002; 51:1111–119.
29. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. *Diabetologia*. 2007; 50:797–805.
30. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. *Physiol Rev*. 2015; 95:513–48.

31. Gamble JM, Clarke A, Myers KJ, Agnew MD, Hatch K, Snow MM, et al. Incretin-based medications for type 2 diabetes: an overview of reviews. *Diabetes Obes Metab*. 2015; 17:649–58.

CHAPTER 13: HBA1C V/S TIR

Decision Making Abilities Using Time in Range

1. Yoo JH, Kim JH. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control. *Diabetes Metab J*. 2020;44(6):828-39.
2. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019; 42(8): 1593-603.
3. Wright Jr. EE, Morgan K, Fu DK, Wilkins N, Guffey WJ. Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making. *Clin Diabetes*. 2020; 38(5): 439-48.
4. Chawla M, Saboo B, Jha S, Bhandari S, Kumar P, Kesavadev J, et al. Consensus and recommendations on continuous glucose monitoring. *J Diabetol*. 2019; 10:4-14.
5. Zhou Z, Sun B, Huang S, Zhu C, Bian M. Glycemic variability: adverse clinical outcomes and how to improve it? *Cardiovasc Diabetol*. 2020; 19:102.
6. Umpierrez GE, Kovatchev BP. Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes. *Am J Med Sci*. 2018; 356(6):518–27.
7. Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. *Acta Diabetol*. 2013; 50:437-42.
8. Hanna FWF, Geen J, Issa BG, Tehrani AA, Fryer AA. Limitations of glycosylated hemoglobin (HbA1c) in diabetes screening. *Practical Diabetes*. 2012; 29(1):29–31.
9. Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch IB, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. *BMJ Open Diabetes Res Care*. 2020; 8(1):e000991.
10. Gabbay MAL, Rodacki M, Calliari LE, Vianna AGD, Krakauer M, Pinto MS, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. *Diabetol Metab Syndr*. 2020; 12: 22.
11. Saboo B, Kesavadev J, Shankar A, Krishna MB, Sheth S, Patel V, et al. Time-in-range as a target in type 2 diabetes: An urgent need. *Heliyon*. 2021;7(1):e05967.
12. Bergenstal RM. Understanding Continuous Glucose Monitoring Data. In: *Role of Continuous Glucose Monitoring in Diabetes Treatment*. Arlington (VA): American Diabetes Association; 2018 Aug. Online available at: <https://www.ncbi.nlm.nih.gov/books/NBK538967/>.
13. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. *Diabetes Technol Ther*. 2019; 21(2):81-85.
14. Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. *J Di-*

abetes Sci Technol. 2019 Jul;13(4):614-26.

15. Advani A. Positioning time in range in diabetes management. *Diabetologia*. 2020; 63:242–52.

Importance of HbA1c in Diabetes Management

1. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. *Biochem Biophys Res Commun*. 1969; 36(5):838-43.
2. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. *N Engl J Med*. 1976; 295(8):417-20.
3. Little RR. Glycated hemoglobin standardization--National Glycohemoglobin Standardization Program (NGSP) perspective. *Clin Chem Lab Med*. 2003; 41(9):1191-198.
4. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights*. 2016; 11:95-104.
5. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021; 44(Suppl 1):S15-S33.
6. Juarez DT, Demaris KM, Goo R, Mnatzaganian CL, Smith HW. Significance of HbA1c and its measurement in the diagnosis of diabetes mellitus: US experience. *Diabetes Metab Syndr Obes*. 2014; 7:487-94.
7. Herman WH, Fajans SS. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. *Pol Arch Med Wewn*. 2010; 120(1-2):37-40.
8. Pimentel AL, Carvalho LSAK, Marques SS, Franco RF, Silveiro SP, Manfro RC, et al. Role of glycated hemoglobin in the screening and diagnosis of posttransplantation diabetes mellitus after renal transplantation: A diagnostic accuracy study. *Clin Chim Acta*. 2015; 445:48-53.
9. Borai A, Livingstone C, Abdelaal F, Bawa-zeer A, Keti V, Ferns G. The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance. *Scand J Clin Lab Invest*. 2011; 71(2):168-72.
10. Fong A, Serra AE, Gabby L, Wing DA, Berkowitz KM. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. *Am J Obstet Gynecol*. 2014; 211(6):641.e1-7.
11. Kwon SS, Kwon J-Y, Park Y-W, Kim Y-H, Lim J-B. HbA1c for diagnosis and prognosis of gestational diabetes mellitus. *Diabetes Res Clin Pract*. 2015; 110(1):38-43.
12. Bozkaya G, Ozgu E, Karaca B. The association between estimated average glucose levels and fasting plasma glucose levels. *Clinics (Sao Paulo)*. 2010; 65(11):1077-080.
13. Kim H-Y, Lee S-Y, Suh S, Kim JH, Lee MK, Park H-D. The relationship between estimated average glucose and fasting plasma glucose. *Clin Chem Lab Med*. 2013; 51(11):2195-200.
14. Hornberger LK. Maternal diabetes and the fetal heart. *Heart*. 2006; 92(8):1019-021.
15. Rizzo G, Pietropolli A, Capponi A, Cacciatore C, Arduini D, Romanini C. Analysis of factors influencing ventricular filling pat-

- terns in fetuses of type I diabetic mothers. *J Perinat Med.* 1994; 22(2):149-57.
16. Leiper JM, Lowe GD, Anderson J, Burns P, Cohen HN, Manderson WG, et al. Effects of diabetic control and biosynthetic human insulin on blood rheology in established diabetics. *Diabetes Res.* 1984; 1(1):27-30.
 17. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? *World J Diabetes.* 2014; 5(4):444-70.
 18. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med.* 2010; 362(9):800-11.
 19. Li X, Xu X, Liu J, Yang J, Fang L, Miao L, et al. HbA1c and survival in maintenance hemodialysis patients with diabetes in Han Chinese population. *Int Urol Nephrol.* 2014;46(11):2207-214.
 20. Kaiafa G, Veneti S, Polychronopoulos G, Pilalas D, Daios S, Kanellos I, et al. Is HbA1c an ideal biomarker of well-controlled diabetes? *Postgrad Med J.* 2021; 97(1148):380-38321.
 21. American Diabetes Association. Standards of Medical Care in Diabetes-2021. *Diabetes Care.* 2021; 44(Supplement 1):S73-S84.
 22. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. *Endocr Pract.* 2015; 21 Suppl 1(Suppl 1):1-87.
 23. Chawla R, Madhu S, Makkar B, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. *Indian J Endocrinol Metab.* 2020; 40(1):1-122.
 24. Nice. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. Online available at www.nice.org.uk/guidance/NG18.
 25. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. *Clin Exp Med.* 2007; 7(1):24-9.
 26. Kompoti M, Michalia M, Salma V, Diogou E, Lakoumenta A, Clouva-Molyvdas P-M. Glycated hemoglobin at admission in the intensive care unit: clinical implications and prognostic relevance. *J Crit care.* 2015; 30(1):150-55.
 27. Lu ZH, Liu N, Bai R, Yao Y, Li SN, Yu RH, et al. HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. *Herz.* 2015; 40 Suppl 2:130-36.
 28. Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, et al. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. *Coron Artery Dis.* 2011; 22(3):131-37.
 29. Timmer JR, Hoekstra M, Nijsten MWN, van der Horst ICC, Ottervanger JP, Slingerland RJ, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. *Circulation.* 2011; 124(6):704-11.
 30. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Inten-

- sive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. *Diabetes Care*. 2009;32(1):187-92.
31. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998; 352(9131):837-53.
 32. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, et al. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine*. 1993; 329(14):977-86.
 33. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008; 358(24):2560-572.
 34. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, et al. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*. 2016; 39(5):694-700.
 35. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009; 373(9677): 1765-772.
 36. Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaiei S. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. *Diab Vasc Dis Res*. 2013; 10(5):397-409.
- ### Decision-Making Modality In Diabetes - Hba1c Vs. Time In Range Expert's Opinion
1. Kesavadev J, Shankar A, Ashok AD, Srinivas S, Ajai NA, Sanal G, et al. Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. *J Diabetes Sci Technol*. 2018; 12(1):230-31.
 2. Davis J, McDonald JM, Jarett L. A high-performance liquid chromatography method for hemoglobin A1c. *Diabetes*. 1978; 27(2):102-07.
 3. Beccaria L, Chiumello G, Gianazza E, Luppis B, Righetti PG. Hemoglobin A1c separation by isoelectric focusing. *Am J Hematol*. 1978; 4(4):367-74.
 4. World Health Organization. Diabetes mellitus: Report of a WHO study group. *World Health Organ Tech Rep Ser*. 1985; 727:1-113.
 5. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care*. 2000; 23:S32.
 6. Control D, Group CTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993; 329(14):977-86.
 7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998; 352(9131):837-53.

8. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000; 321(7258):405-12.
9. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019; 42(8):1593-603.
10. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. *Diabetes Care*. 2019; 42(3):400-05.
11. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1c to Time-in-Range in Patients with Diabetes. *Diabetes Technol Ther*. 2019; 21(2):81-5.
3. Jethwani P, Saboo B, Jethwani L, Chawla R, Maheshwari A, Agarwal S, et al. Use of insulin glargine during pregnancy: A review. *Diabetes Metab Syndr*. 2021; 15(1):379-84.
4. Alyson K. Insulin Use in Pregnancy: An Update. *Diabetes Spectr*. 2016; 29(2):92-97.
5. Torlone E, Vitacolonna E. New Insulin to Treat Pregestational Diabetes in Pregnancy. In: Lapolla A, Metzger BE, eds: *Gestational Diabetes. A Decade after the HAPO Study*. Front Diabetes. Karger (Basel). 2020; 28:76-87.
6. LANTUS - US Food and Drug Administration. LANTUS® (insulin glargine[rDNAorigin]injection). Rev. March 2007. Online available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021081s024lbl.pdf.
7. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. *Diabetes Care*. 2010; 33(1):29-33.
8. Pöyhönen-Alho M, Rönnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. *Acta Obstet Gynecol Scand*. 2007; 86(10):1171-174.
9. Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F, et al, Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). *Diabetes Metab*. 2011; 37(5):426-31.

CHAPTER 14: GLARGINE IN PREGNANCY: YES/NO

Glargine in Pregnancy

1. Cunningham AM, Freeman AM. Glargine Insulin. [Updated 2021 Apr 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Online available at- <https://www.ncbi.nlm.nih.gov/books/NBK557756/>.
2. Pantea-Stoian A, Stoica RA, Stefan SD. Insulin Therapy in Gestational Diabetes. In: Ray A, ed. *Gestational Diabetes Mellitus - An Overview with Some Recent Advances*. Intechopen. 2020.

10. Pollex E, Moretti ME, Koren G, Feig DS. Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis. *Ann Pharmacother*. 2011; 45(1):9-16.

Glargine in Pregnancy- Not Recommended

1. International Diabetes Federation Atlas 9th Edition. Online available at: www.idf.org/e-library/epidemiology-research/diabetes-atlas/159-idf-diabetes-atlas-ninth-edition-2019.html. Accessed date-20/06/2019.
2. Diagnosis & Management of Gestational Diabetes Mellitus. Technical and Operational Guidelines by Ministry of Health & family welfare, Govt. of India. Online available at: https://nhm.gov.in/New_Updates...Guidelines/Gestational-Diabetes-Mellitus.
3. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with pre-pregnancy diabetes. *Diabetes Care*. 2007; 30(7):1920-925.
4. Hapo Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. *N Engl J Med*. 2008; 358(19):1991-2002.
5. Gough SC. A review of human and analogue insulin trials. *Diabetes Res Clin Pract*. 2007; 77(1):1-15.
6. Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. *Diabetes Care*. 2007; Suppl 2:S220-24.
7. Pollex EK, Feig DS, Lubetsky A, Yip PM, Koren G. Insulin glargine safety in pregnancy: a transplacental transfer study. *Diabetes Care*. 2010; 33(1):29e33.
8. Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P, et al. Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. *Diabetes Care*. 2012; 35(12):2647-649.
9. Bolli GB, Hahn AD, Schmidt R, Eisenblatter T, Dahmen R, Heise T, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. *Diabetes Care*. 2012; 35(12):2626e30.
10. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. *Int J Toxicol*. 2002; 21(3):181-89.
11. Di Cianni G, Volpe L, Lencioni C, Chatzianagnostou K, Cuccuru I, Ghio A, et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. *Diabetes Care*. 2005; 28(4):982-83.
12. Gallen IW, Jaap A, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with Type 1 diabetes. *Diabet Med*. 2008; 25(2):165-69.
13. Chico A, Herranz L, Corcoy R, Ramírez O, Goya MM, Bellart J, et al. GEDE (Group of Diabetes and Pregnancy of the Spanish Diabetes Association). Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. *Eur J Obstet Gynecol Reprod Biol*. 2016; 206:84-91.

14. Poyhonen-Alho M, Ronnema T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. *Acta Obstet Gynecol Scand.* 2007; 86(10):1171-174.
15. Callesen NF, Damm J, Mathiesen JM, Ringholm L, Damm P, Mathiesen ER. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. *J Matern Fetal Neonatal Med.* 2013; 26(6):588-92.
16. American Diabetes Association. 14. Management of diabetes in pregnancy: standards of medical care in diabetes-2020. *Diabetes Care.* 2020; 43(Suppl 1): S183-92.
17. National Institute for Health and Care Excellence (Nice) Guidelines. Diabetes in pregnancy: management from preconception to the postnatal period. 2015. Online available at: <https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-from-preconception-to-the-postnatal-period-pdf-51038446021>.
18. Diabetes Canada Clinical Practice Guidelines Expert Committee; Feig DS, Berger H, Donovan L, Godbout A, Kader T, Keely E, et al. Diabetes and pregnancy. *Can J Diabetes.* 2018; 42(Suppl 1):S255-82.
3. Buchanan TA, Kjos SL. Diabetes in women. Early detection, prevention, and management. *Clin Updates Women's Health Care.* 2002; 1(4/Fall):47.
4. Holstein A, Plaschke A, Egberts E-H. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. *Diabet Med.* 2003; 20:779-80.
5. Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's disease. *Diabetes Care.* 2005; 28:2084-085.
6. Al-Shaikh AA. Pregnant women with type 1 diabetes mellitus treated by glargine insulin. *Saudi Med J* 2006; 27:563-65.
7. Graves DE, White JC, Kirk JK. The use of insulin glargine with gestational diabetes mellitus. *Diabetes Care.* 2006; 29:471-72.
8. Pollex E, Moretti ME, Koren G, Feig DS. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. *An Pharmacother.* 2011; 45:9-16.
9. Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. *Obstet Gynecol Int.* 2012; 2012:649070.

Controversy: Insulin glargine in Pregnancy

1. Product information. Lantus. Sanofi-Aventis. Online available at: <https://products.sanofi.us/lantus/lantus.html>.
2. Schardein JL. Insulin and oral hypoglycemic agents. In: *Chemically Induced Birth Defects.* 3rd ed. New York, NY: Marcel Dekker. 2000:458.
10. Callesen NF, Damm J, Mathiesen JM, Ringholm L, Damm P, Mathiesen ER. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome. *J Matern Fetal Neonatal Med.* 2013; 26:588-92.

11. Lambert K, Holt RIG. The use of insulin analogues in pregnancy. *Diabetes Obes Metab.* 2013; 15:888–900.
12. Insulin glargine / lixisenatide Pregnancy and Breastfeeding Warnings, Medically reviewed by Drugs.com. Last updated on Apr 6, 2020. Online available at: <https://www.drugs.com/pregnancy/insulin-glargine-lixisenatide.html>.
13. Cerner Multum, Inc. “UK Summary of Product Characteristics.”
14. United States National Library of Medicine Toxnet. Toxicology Data Network. Online available at: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT>.
15. Cerner Multum, Inc. Australian Product Information.
16. Diagnosis and management of gestational diabetes mellitus: technical and operational guidelines: Maternal Health Division, Ministry of Health & Family Welfare, Government of India, February, 2018. Online available at: https://nhm.gov.in/New_Updates_2018/NHM_Components/RMNCH_MH_Guidelines/Gestational-Diabetes-Mellitus.pdf.
17. Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. *Int J Endocrinol.* 2012; 2012:296368.
18. Product Information. Toujeo SoloStar (insulin glargine). Sanofi-Aventis, U.S. LLC Bridgewater, NJ 08807, 2019. Online available at: <https://products.sanofi.us/toujeo/toujeo.pdf>.

CHAPTER 15: PIOGLIAZONE- USE IN TYPE 2 DIABETES MELLITUS - WHERE TO PLACE IT?

1. Joshi SR. Diabetes Care in India. *Ann Glob Health.* 2015; 81(6):830-38.
2. Davies MJ, D'Alessio DA, Fradkin J, , Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018; 41 (12):2669-701.
3. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians:similarities and differences with white Caucasian and other populations. *Ann N Y Acad Sci.* 2013; 1281(1):51–63.
4. Schernthaner G, Currie CG, Schernthaner GH. Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 *Diabetes Care.* 2013;36(2):s155-s161.
5. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. *Diabetologia.* 2005;48: 1093–104.
6. Alam F, Islam MA, Mohamed M, Ahmad I, Kamal MA, Donnelly R, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systemic review and meta-analysis of randomized controlled trials. *Sci Rep.* 2019; 9:5389.

7. Paniker V, Kale NJ, Hoskote SS, Deogaonkar N, Joshi SR. Effect of Low (7.5 mg/day), Standard (15 mg/day) and High (30 mg/day) Dose Pioglitazone Therapy on Glycemic Control and Weight Gain in Recently-Diagnosed Type 2 Diabetes Patients. *J Assoc Physicians India*. 2015; 63:36-39.
8. Pai SA, Kshirsagar NA. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. *Indian J Med Res*. 2016; 144(5):672-81.
9. DeFronzo RA, Inzucchi S, Ghani MA, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. *Diab Vasc Dis Res*. 2019;16(2):133-43.
10. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. *Hypertens Res*. 2007; 30:387-94.
11. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, et al.; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. *Diabetes Care*. 2007; 30:2458-464.
12. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. *Lancet*. 2005; 366:1279-289.
13. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman, et al. Pioglitazone after ischemic stroke or transient ischemic attack. *New Engl J Med*. 2016; 374:1321-331.
14. Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (insulin resistance intervention after stroke). *Circulation*. 2018; 137:455-63.
15. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ*. 2009; 339: b4731.
16. Strongman H, Christopher S, Majak M, Williams R, Bahmanyar S, Linder M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multi database cohort study. *BMJ Open Diabetes Res Care*. 2018; 6:e000481.
17. Liao HW, Saver JL, Wu YL, Chen T-H, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open*. 2017; 7:e013927.
18. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE ran-

- domized controlled trial. *JAMA*. 2008; 299:1561–573.
19. Mazzone T, Meyer PM, Feinsein SB, Davidson MH, Kondos GT, D'Agostino Sr RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima media thickness in type 2 diabetes: a randomized trial. *JAMA*. 2006; 296:2572–581.
 20. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Prato SD, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*. 2017; 5:887–97.
 21. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease- Data from Proactive study (PROactive 08). *Diabetes Care*. 2007; 30:2773–778.
 22. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Circulation*. 2003; 108:2941–948.
 23. Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. *J Clin Endocrinol Metab*. 2017; 102(3):914–22.
 24. Lewis JD, Ferrara A, Peng T, Hedderston M, Bilker WB, Quesenberry Jr CP, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. *Diabetes Care*. 2011; 34:916–22.
 25. Balaji V, Seshiah V, Ashtalakshmi G, Ramanan SG, Janarthanakani M, et al. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. *Indian J Endocrinol Metab*. 2014; 18(3):425–27.

Pioglitazone: Current Place in Diabetes Management

1. Devchand PR, Liu T, Altman RB, FitzGerald GA, Schadt EE. The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond. *Front Pharmacol*. 2018; 9:1093.
2. List of new drugs approved in India from 1991 to 2000. Online available at- <https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadApprovalNewDrugs/1991-2000.pdf>. Accessed date- 1/04/2021.
3. Karásek D. Pioglitazone. *Vnitř Lek*. 2020; 66(2):121-25.
4. Choi SS, Park J, Choi JH. Revisiting PPAR α as a target for the treatment of metabolic disorders. *BMB Rep*. 2014; 47(11):599-608.
5. Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. *J Am Coll Cardiol*. 2008; 52(10):869-81.
6. Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety

- and efficacy review. *Clin Med Insights Endocrinol Diabetes*. 2010; 3:43-51.
7. Czaja MJ. Pioglitazone: more than just an insulin sensitizer. *Hepatology*. 2009; 49(5):1427-430.
 8. Alam F, Islam MA, Mohamed M, Ahmad I, Kamal MA, Donnelly R, et al. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. *Sci Rep*. 2019; 9(1):5389.
 9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet*. 2005; 366(9493):1279-289.
 10. Scheen AJ, Tan MH, Betteridge DJ, Birke-land K, Schmitz O, Charbonnel B; PROactive investigators. Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). *Diabet Med*. 2009; 26(12):1242-249.
 11. Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, et al; PROactive investigators. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). *J Clin Endocrinol Metab*. 2010; 95(5):2163-171.
 12. Perriello G, Pampanelli S, Di Pietro C, Brunetti P, Italian Pioglitazone Study Group. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. *Diabet Med*. 2006; 23(3):246-52.
 13. Göke B, Lübben G, Bates PC. Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. *Exp Clin Endocrinol Diabetes*. 2004; 112(2):115-17.
 14. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. *Diabetes Care*. 2002; 25(3):517-23.
 15. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. *Circulation*. 2008; 117(16):2123-130.
 16. Hanefeld M, Marx N, Pfützner A, Bau-recht W, Lübben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. *J Am Coll Cardiol*. 2007; 49(3):290-97.
 17. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA*. 2008; 299(13):1561-573.
 18. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media

- thickness in type 2 diabetes: a randomized trial. *JAMA*. 2006; 296(21):2572-581.
19. de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. *Cardiovasc Diabetol*. 2017; 16(1):134.
 20. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al; IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med*. 2016; 374(14):1321-331.
 21. Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, et al; IRIS Trial Investigators. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). *Circulation*. 2018; 137(5):455-63.
 22. Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, et al; IRIS Investigators. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. *Circulation*. 2017; 135(20):1882-893.
 23. Morgan CL, Inzucchi SE, Puelles J, Jenkins-Jones S, Currie CJ. Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. *Diabetes Obes Metab*. 2018; 20(9):2140-147.
 24. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ*. 2009; 339:b4731.
 25. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. *J Clin Endocrinol Metab*. 2012; 97(12):4605-612.
 26. Strongman H, Christopher S, Majak M, Williams R, Bahmanyar S, Linder M, et al. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multi-database cohort study. *BMJ Open Diabetes Res Care*. 2018; 6(1):e000481.
 27. Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, Yu S. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study. *Curr Med Res Opin*. 2014; 30(11):2223-231.
 28. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007; 298(10):1180-188.
 29. Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open*. 2017; 7(1):e013927.
 30. Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. *Int J Mol Sci*. 2021; 22(5):2350.

31. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018; 67(1):328-57.
32. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016; 64(6):1388-402.

Pioglitazone- Use in Type 2 Diabetes Mellitus

1. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. *J Clin Endocrinol Metab*. 2004; 89:6068-076.
2. Yamanouchi T, Sakai T, Igarashi K, Ichiyonagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. *Diabet Med*. 2005; 22: 980-85.
3. Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. *Exp Clin Endocrinol Diabetes*. 2014; 122:295-302.
4. Kim NH, Kim DL, Kim KJ, Kim NH, Choi KM, Baik SH, et al. Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study. *Endocrinol Metab*. 2017; 32:241-47.
5. Genovese S, De Berardis G, Nicolucci A, Mannucci E, Evangelista V, Totani L, et al. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes. *Adv Ther*. 2013; 30:190-202.
6. Charbonnel BH, Matthews D, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. *Diabet Med*. 2005; 22:399-405.
7. Tan M, Johns D, Gálvez GG, Antúnez O, Fabián G, Flores-Lozano F, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. *Clin Ther*. 2004; 26:680-93.
8. Perez A, Jacks R, Arora V, Spanheimer R. Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared With Pioglitazone and Metformin Monotherapy in Patients With Type 2 Diabetes. *J Clin Hypertens*. 2010; 12:973-82.
9. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of

- insulin sensitivity in recently diagnosed patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2003; 88:1637–645.
10. You SH, Kim BS, Hong SJ, Ahn C-M, Lim D-S. The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis. *Korean Circ J.* 2010; 40:625–31.
 11. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. *Am J Med.* 2003; 115:42–48.
 12. Kushner RF, Sujak M. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. *Obesity.* 2009; 17:1017–022.
 13. Asnani S, Richard BC, Desouza C, Fonseca V. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. *Curr Med Res Opin.* 2003; 19:609–13.
 14. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2003; 88(4):1637–645.
 15. Al Majali K, Cooper MB, Staels B, Luc G, Taskinen M-R, Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. *Diabetologia.* 2006; 49:527–37.
 16. Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. *J Diabetes Investig.* 2014; 5:327–32.
 17. Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. *J Endocrinol Invest.* 2014; 37:1211–218.
 18. Esteghamati A, Afarideh M, Feyzi S, Noshad S, Nakhjavani M. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. *Diabetes Metab Syndr.* 2015; 9:258–65.
 19. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. *Clin Ther.* 2002; 24:378–96.
 20. Langenfeld M, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. *Circulation.* 2005; 111:2525–531.
 21. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino Sr RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA.* 2006; 296:2572–581.

22. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino Sr R, Kondos GT, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. *Circulation*. 2008; 117:2123–130.
23. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med*. 2010; 363:1410–418.
24. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA*. 2007; 298:1180–188.
25. Mannucci E, Monami M, Lamanna C, Gensini G, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2008; 10:221–238.
26. Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. *Diabetes Ther*. 2017; 8:705–26.
27. Cryer PE. Hypoglycemia, functional brain failure, and brain death. *J Clin Invest*. 2007; 117:868–70.
28. Yanai H, Adachi H. The Low-Dose (7.5 mg/day) Pioglitazone Therapy. *J Clin Med Res*. 2017; 9:821-25.

CHAPTER 16: SULFONYLUREAS IN COST EFFECTIVE SETTING ONLY OR UNIVERSAL

Sulfonylureas in Cost Effective Setting Only or Universal–Yes

1. Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. *Ann N Y Acad Sci*. 2013; 1281:36-50.
2. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. *Metabolism*. 2006; 55(5 Suppl 1):S20-27.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2012; 55:1577-596.
4. Valensi P, Slama G. Sulphonylureas and cardiovascular risk: facts and controversies. *The British Journal of Diabetes & Vascular Disease*. 2006;6(4):159-165.
5. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998; 352:837-53.
6. Douros A, Yin H, Yu OHY, Filion KB, Azoulay L, Suissa S. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. *Diabetes Care*. 2017; 40:1506–513.

7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med.* 2006; 355:2427-443.
8. Wright AD, Cull CA, Macleod KM, Holman RR, UKPDS. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. *Diabetes Complications.* 2006; 20:395-401.
9. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care.* 2009; 32:84-90.
10. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. *Pharmacogenomics.* 2009; 10(11):1781-787.
11. Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. *Diabetes Obes Metab.* 2012; 14:130-38.
12. Emdin CA, Klarin D, Natarajan P, CARDIOGRAM Exome Consortium; Florez JC, Kathiresan S, et al. Genetic variation at the sulfonylurea receptor, type 2 diabetes, and coronary heart disease. *Diabetes.* 2017; 66:2310-315.
13. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. *Diabetes Obes Metab.* 2010; 12(5):431-36.
14. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. *Endocr Pract.* 2017;23: 207-38.
15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012;35: 1364-379.

Use of Sulphonylureas- In Selected Population

1. White Jr JR. A Brief History of the Development of Diabetes Medications. *Diabetes Spectr.* 2014; 27(2):82-86.
2. Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006; 449.
3. UKPDS.
4. ADVANCE Collaborative Group; Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2008; 358:2560-572.

5. American Diabetes Association. Standards of Medical Care in Diabetes—2014. *Diabetes Care*. 2014; 37(Supplement 1): S14-S80.
6. American Diabetes Association. Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. *Diabetes Care* 2020;43(Suppl. 1):S98-S110.
7. *Diabetes Care*. 2020; 43(8):1979.
8. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. *Endocrine Pract*. 2020; 26:107-139.
9. Harrower AD. Comparative Tolerability of sulphonylureas in diabetes mellitus. *Drug Saf*. 2000; 22(4):313-20.
10. Webb R David, Davies J.Melanie, Janet Jarvis, Seidu S, Khunti K. The right place for sulphonylureas today. *Diabetes Res Clin Pract*. 2019; 157:107836.
11. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland M, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. The CAROLINA Randomized Clinical Trial. *JAMA*. 2019; 322(12):1155-166.
12. Schernthaner G, Grimaldi A, Di Mario U, J Drzewoski, P Kempler, M Kvapil, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in Type 2 diabetic patients. *Eur J Clin Invest*. 2004; 34:535-42.
13. Dash SC, Agarwal SK, Panigrahi A, Mishra J, Dash D. Diabetes, Hypertension and Kidney Disease Combination “DHKD Syndrome” is common in India. *J Assoc Physicians India*. 2018; 66(3):30-33.
14. Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. *Journal of Applied Pharmaceutical Science*; 01(09):11-19.

SULPHONYLUREAS IN COST EFFECTIVE SETTINGS ONLY OR UNIVERSAL

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008; 359(15):1577-589.
2. Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? reflections from a Diabetes Care editors' Expert Forum. *Diabetes Care*. 2018; 41(1):14-31.
3. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018; 41(12):2669-701.
4. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. *JAMA*. 2019; 322(12):1155-166.

5. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA*. 2016; 316(3):313-24.
6. Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. *Diabetes Obes Metab*. 2014; 16(9):833-40.
7. Douros A, Yin H, Yu OH, Filion KB, Azoulay L, Suissa S. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. *Diabetes Care*. 2017; 40(11):1506-513.
8. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. *Diabetes Care*. 2007; 30(2):389-94.
9. van Staa T, Abenham L, Monette J. Rates of hypoglycemia in users of sulfonylureas. *J Clin Epidemiol*. 1997; 50(6):735-41.
10. Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. *Diabetes Res Clin Pract*. 2015; 110(1):75-81.
11. Naidoo P, Rambiritch V, Butkow N, Saman S. Optimal utilisation of sulphonylureas in resource-constrained settings. *Cardiovasc J Afr*. 2014; 25(2):83-5.
12. Apovian CM, Okemah J, O'Neil PM. Body Weight Considerations in the Management of Type 2 Diabetes. *Adv Ther*. 2019; 36(1):44-58.
13. Aladhab RA, Alabood MH. Adherence of patients with diabetes to a lifestyle advice and management plan in Basra, Southern Iraq. *Int J Diabetes Metab*. 2019;25:100-105.
14. Cavaiola TS, Pettus JH. Management Of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. [Updated 2017 Mar 31]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 5, Cost per month of various diabetes medications. Online available at: <https://www.ncbi.nlm.nih.gov/books/NBK425702/table/type2-diab-mgmt-pharm.classdrugm/>
15. Zozaya N, Capel M, Simón S, Soto-González A. A systematic review of economic evaluations in non-insulin anti-diabetic treatments for patients with type 2 diabetes mellitus. *Global & Regional Health Technology Assessment: Italian, Northern Europe and Spanish*. 2019;
16. Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmaco-economic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. *J Family Med Prim Care*. 2019; 8:955-59.
17. Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line anti-hyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. *CMAJ*. 2011; 183(16):E1213-220.

CHAPTER 17: DIABETES MELLITUS REVERSAL- ATTAINABLE IN PRIMARY CARE/STILL A WAY TO GO?

Diabetes Reversal

1. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. *Diabetologia*. 2008; 51:1781–789.
2. White MG, Shaw JAM, Taylor R. Type 2 Diabetes: The Pathologic Basis of Reversible b-Cell Dysfunction. *Diabetes Care*. 2016; 39:2080–088.
3. Nagi D, Hambling C, Taylor R. Remission of Type 2 Diabetes: A Position Statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS). *The British Journal of Diabetes*. 2019; 19.
4. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How Do We Define Cure of Diabetes? *Diabetes Care*. 2009; 32(11):2133-135.
5. Ang GY. Reversibility of diabetes mellitus: Narrative review of the evidence. *World J Diabetes*. 2018; 9(7):127-31.
6. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia*. 2011; 54:2506–514.
7. Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. *Diabet Med*. 2019; 36(3):308-15.
8. Sarathi V, Kolly S, Chaithanya HB, Dwarkanath CS. High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy. *J Nat Sci Biol Med*. 2017; 8(1):60-63.
9. Taylor R. Calorie restriction for long-term remission of type 2 diabetes. *Clin Med (Lond)*. 2019; 19(1):37-42.
10. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes Endocrinol*. 2019; 7(9):726-36.
11. Taylor R. Type 2 Diabetes: Etiology and reversibility. *Diabetes Care*. 2013; 36(4):1047-055.
12. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. *Cell Metab*. 2018; 28:547–56.e3.
13. Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and non-responders. *Diabetes Care*. 2016; 39:808–15.
14. Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol*. 2018; 6: 361-69.

Diabetes Reversal in Primary Care—A Myth

1. International Diabetes Federation. *IDF Diabetes Atlas*. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.

2. World Health Organization Global Report on Diabetes 2016. Online available at : <https://www.who.int/publications/i/item/9789241565257>. Accessed date-06/07/2020.
3. Doctor-patient ratio in India less than WHO-prescribed norm of 1:1000: Govt. Online available at: <https://health.economicstimes.indiatimes.com/news/industry/doctor-patient-ratio-in-india-less-than-who-prescribed-norm-of-11000-govt/72135237>. Accessed date-29/04/2021.
4. Deo MG. Doctor population ratio for India-the reality. *Indian J Med Res.* 2013 Apr;137(4):632-35.
5. Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: a focused literature review. *The British Journal of Diabetes.* 2015; 15(2):65-9.
6. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. *Diabetes Care.* 2013; 36(11):3411-417.
7. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care.* 2020; 43(Suppl 1):S14-S31.
8. DeFronzo RA. Banting Lecture: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009; 58(4):773-95.
9. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jequier E, et al. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. *Metabolism.* 1990; 39(10):1068-075.
10. Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing type 2 diabetes: A narrative review of the evidence. *Nutrients.* 2019; 11(4):766.
11. Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. *JAMA.* 2018; 319(3):241-54.
12. Purnell JQ, Selzer F, Wahed AS, Pender J, Pories W, Pomp A, et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the longitudinal assessment of bariatric surgery study. *Diabetes Care.* 2016; 39(7):1101-017.
13. Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. *N Engl J Med.* 2017; 376:641-51.
14. Gumbs AA, Pomp A, Gagner M. Revisional bariatric surgery for inadequate weight loss. *Obes Surg.* 2007; 17(9):1137-145.
15. Eisenberg D, Azagury DE, Ghiassi S, Grover BT, Kim JJ. ASMBS position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery.
16. *Surg Obes Relat Dis.* 2017; 13(3):371-78.
17. Sjostrom L, Lindroos AK, Peltonen M, Jarl Torgerson, Claude Bouchard, et al; Swedish Obese Subjects Study scientific

- group, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med*. 2004; 351:2683-693.
18. Bistrian BR, Blackburn GL, Flatt JP, Sizer J, Scrimshaw NS, Sherman M. Nitrogen metabolism and insulin requirements in obese diabetic adults on a protein-sparing modified fast. *Diabetes*. 1976; 25(6):494-504.
 19. Hughes TA, Gwynne JT, Switzer BR, Herbst C, White G. Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. *Am J Med*. 1984; 77(1):7-17.
 20. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. *J Am Coll Cardiol*. 2008; 52(12):1006-012.
 21. Snel M, Jonker JT, Hammer S, Kerper-shoek G, Lamb HJ, Meinders AE, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. *Obesity (Silver Spring)*. 2012; 20(8):1572-576.
 22. Paisey RB, Harvey P, Rice S, Belka I, Bower L, Dunn M, et al. An intensive weight loss programme in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year. *Diabet Med*. 1998;15(1):73-9.
 23. Bhatt AA, Choudhari PK, Mahajan RR, Sayyad MG, Pratyush DD, Hasan I, et al. Effect of a low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes. *Indian J Endocrinol Metab*. 2017; 21(5):776-80.
 24. Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. *BMJ Open Diabetes Res Care*. 2017;5(1):e000354.
 25. Nielsen JV, Joensson EA. Low-carbohydrate diet in type 2 diabetes: stable improvement of bodyweight and glycemic control during 44 months follow-up. *Nutr Metab (Lond)*. 2008; 5:14.
 26. Sanada M, Kabe C, Hata H, Uchida J, Inoue G, Tsukamoto Y, et al. Efficacy of a moderately low carbohydrate diet in a 36-month observational study of Japanese patients with Type 2 diabetes. *Nutrients*. 2018; 10(5):528.
 27. Tay J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Noakes M, Buckley JD, et al. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: a 2-year randomized clinical trial. *Diabetes Obes Metab*. 2018; 20(4):858-71.
 28. Sahay BK. Dietary carbohydrate content in Indian diabetic patients. *Medicine*. 2012; 22:235-39.
 29. Damms-Machado A, Weser G, Bischoff SC. Micronutrient deficiency in obese subjects undergoing low calorie diet. *Nutr J*. 2012; 11(1):34.
 30. Gardner CD, Kim S, Bersamin A, Dople-Nelson M, Otten J, Oelrich B, et al. Micronutrient quality of weight-loss diets that focus on macronutrients: results

from the A TO Z study. *Am J Clin Nutr.* 2010; 92(2):304-12.

31. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. *Phys Ther.* 2008; 88(11):1254-264.

CHAPTER 18: QUADRUPLE THERAPY - YES/NO

Quadruple Therapy Diabetes: Yes or No?

1. International Diabetes Federation. *IDF Diabetes Atlas*, 10th edn. Brussels, Belgium: 2021. Available at: <https://www.diabetesatlas.org>
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *The Lancet.* 1998;352:837-865.
3. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes.* 1988;37:667-687. Abstract.
4. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes.* 2009;58:773-95.
5. Kalra S, Chawla R, Madhu SV. The dirty dozen of diabetes. *Indian J Endocrinol Metab.* 2013;17(3):367-369.
6. Unnikrishnan AG. Tissue-specific insulin resistance. *Postgraduate Medical Journal* 2004;80:435.
7. Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. *Diabetes Obes Metab.* 2015; 17(3):268-75.
8. Ku EJ, Lee DH, Jeon HJ, Oh TK. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice. *Diabetes Obes Metab.* 2019 Jan;21(1):173-177.
9. Ku EJ, Lee DH, Jeon HJ, Oh TK. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. *Diabetes Res Clin Pract.* 2019 May;151:65-73.
10. Cho YK, Lee J, Kim HS, Park JY, Jung CH, Lee WJ. Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study. *Diabetes Ther.* 2020 Sep;11(9):2029-2039.
11. Bae J, Huh JH, Lee M, Lee YH, Lee BW. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial. *Diabetes Obes Metab.* 2021 Feb;23(2):609-618.
12. Moon JS, Suh S, Kim SS, Jin HY, Kim JM, Jang MH, Lee KA, Lee JH, Chung SM, Lyu YS, Kim JH, Kim SY, Jang JE, Kim

- TN, Kim SW, Jeon E, Cho NH, Kim MK, Kim HS, Nam-Goong IS, Kim ES, Chung JO, Cho DH, Lee CW, Kim YI, Chung DJ, Won KC, Kim IJ, Park TS, Kim DK, Shon H. Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study. *Diabetes Metab J*. 2021 Sep;45(5):675-683.
13. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. *Lancet*. 2008 May 24; 371(9626):1725-6.
 14. Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. *Am J Cardiol*. 2007;99:15B-26B.
 15. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. *Diabetes Care* 2020;43(Suppl 1):S98-110.
 16. Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020 [published correction appears in *Indian J Endocrinol Metab*. 2020 Jul-Aug;24(4):376]. *Indian J Endocrinol Metab*. 2020;24(1):1-122.
 17. Origin Trial Investigators. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367:319-328.
 18. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. *Diabetes Care*. 2008;31:1927-1932.
 19. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. Beta-cell function preservation after 3.5 years of intensive diabetes therapy. *Diabetes Care*. 2012;35:1406-1412.
 20. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. *JAMA Intern Med*. 2015;175:356-362.

Relevance of Quadruple Therapy in the Management of Type 2 Diabetes Mellitus

1. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. *Curr Cardiol Rep*. 2019; 21(4):21.
2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001; 344(18):1343-350.
3. Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. *JAMA*. 2014; 311(22):2315-325.
4. Kuo S, Yang CT, Wu JS, Ou H-T. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: a nationwide population-based, propensity-score-matched cohort study. *Diab Obesity Metabol*. 2019; 21(2):312-20.
5. Kim NH, Lim S, Kwak SH, Moon MN, Moon JS, Lee Y-H, et al. Efficacy and tolerability of novel triple combination therapy in drug-naive patients with type

- 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomized controlled trial. *BMJ Open*. 2018; 8(9):e022448.
6. Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. *Peer J*. 2015; 3:e1461.
 7. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018; 41:2669–701.
 8. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to the management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2020; 43(2):487–493.
 9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015; 38(1):140–49.
 10. American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. *Clin Diab*. 2015; 33(2):97–111.
 11. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan-2015—Executive Summary. *Endocrine Pract*. 2015; 21(4):413–37.
 12. Ku EJ, Lee DH, Jeon HJ, Oh TK. Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice. *Diab Obes Metabol*. 2019; 21(1):173–77.
 13. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes*. 2009; 58(4):773–95.
 14. Kumar A. Second-line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. *Diabetes Metab Res Rev*. 2012; 28 Suppl 2:21–5.
 15. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. *Pharmacotherapy*. 2010; 30(5):463–84.
 16. Migoya EM, Bergeron R, Miller JL, Snyder RNK, Tanen M, Hilliard D, et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. *Clin Pharmacol Ther*. 2010; 88(6):801–08.
 17. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 dia-

- betes. *J Clin Endocrinol Metabol.* 2012; 97(5):1615-622.
18. Qian D, Zhang T, Zheng P, Liang Z, Wang S, Xie J, et al. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. *Diabetes Ther.* 2018; 9(5):1945-958.
 19. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* 2016; 4(5):411-19.
 20. Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. *Int J Cardiol.* 2017; 228:352-58.
 21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015; 373(22):2117-128.
- abetes mellitus: systematic review and meta-analysis. *Diabetes Obes. Metab.* **16**, 410–417 (2014).
3. Matthews, D. R. *et al.* Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. *Lancet* **394**, 1519–1529 (2019).
 4. DeFronzo, R. A., Eldor, R. & Abdul-Ghani, M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. *Diabetes Care* **36 Suppl 2**, S127–38 (2013).
 5. American Diabetes Association Professional Practice Committee *et al.* 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. *Diabetes Care* **45**, S125–S143 (2022).

CHAPTER 19: DIABETES MELLITUS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: SODIUM-GLUCOSE TRANSPORT PROTEIN 2 INHIBITOR VS. GLUCAGON-LIKE PEPTIDE 1 ANALOGUE

Opinion: Quadruple Oral Hypoglycemic Agent Therapy in Diabetes

1. Cho, Y. K. *et al.* Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study. *Diabetes Ther.* **11**, 2029–2039 (2020).
2. Phung, O. J., Sobieraj, D. M., Engel, S. S. & Rajpathak, S. N. Early combination therapy for the treatment of type 2 di-

DM WITH ASCVD : SGLT2 Inhibitor Vs GLP1 Analogue : Favoring GLP1RA

- Lyseng-Williamson KA. *Clin Drug Investig.* 2019 Aug;39(8):805-819. doi: 10.1007/s40261-019-00826-0. PMID: 31317516
- Sharma A, Zhao X, Hammill BG, Hernandez AF, Fonarow GC, Felker GM, Yancy CW, Heidenreich PA, Ezekowitz JA, DeVore AD. Trends in noncardiovascular comorbidities among patients hospitalized

for heart failure: insights from the Get With The Guidelines-Heart Failure Registry. *Circ Heart Fail.* 2018; 11:e004646. doi: 10.1161/CIRCHEARTFAILURE.117.004646

International Diabetes Federation. IDF Diabetes Atlas— 9th Edition. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Accessed 21 Dec 2020.

Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol.* 2019;7(10):776–85.

elniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation.* 2019;139(17):2022–31.

D'Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Paterno E. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol.* 2020;19(1):154.

Management of Diabetes with Atherosclerotic Cardiovascular Disease - Sodium-Glucose Cotransporter-2 Inhibitors

1. International Diabetes Federation. IDF Diabetes Atlas 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.

2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. *Diabetes Care.* 2018; 41:917–28.

3. American Diabetes Association. 9. Cardiovascular Disease and Risk Management: Standards of medical care in Diabetes-2018. *Diabetes Care.* 2018; 41(suppl 1):S86-S104.

4. Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. *Diab Vasc Dis Res.* 2013;10(6):505-13.

5. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus—mechanisms, management, and clinical considerations. *Circulation.* 2016; 133: 2459–502.

6. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. *Drugs.* 2015; 75(1):33–59.

7. Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. *Drug Des Devel Ther.* 2015; 9:5793–803.

8. Triplitt C, Cornell S. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. *Clin Med Insights Endocrinol Diabetes.* 2015; 8:73–81.

9. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor,

- in diabetes mellitus. *Cardiovasc Diabetol.* 2015; 14:142.
10. Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. *Australas Med J.* 2014; 7(10):405–15.
 11. Desouza CV, Gupta N, Patel A. Cardiometabolic Effects of a New Class of Antidiabetic Agents. *Clin Ther.* 2015; 37(6):1178–194.
 12. Baruah MP, Makkar B M, Ghatnatti VB, Mandal K: Sodium Glucose Co-transporter 2 inhibitor: Benefits beyond glycemic control. *Indian J Endocr Metab* 2019;23:140-9.
 13. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. *Curr Opin Endocrinol Diabetes Obes.* 2017; 24(1):73-79.
 14. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Online available at: <https://www.fda.gov/media/71297/download>.
 15. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015; 373:2117–128.
 16. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017; 377:644–57.
 17. Mishra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: determinants and significance. *J Assoc Physicians India.* 2004; 52:137-142
 18. Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. *BMC Genet.* 2002; 3:9.
 19. Bhardwaj S, Misra A, Khurana L, Gulati S, Shah P, Vikram NK. Childhood obesity in Asian Indians: a burgeoning cause of insulin resistance, diabetes and sub-clinical inflammation. *Asia Pac J Clin Nutr.* 2008;17 Suppl 1:172-75.
 20. Mohan V. Why are Indians more prone to diabetes? *J Assoc Physicians India.* 2004; 52:468-74.

Management of Diabetes with Atherosclerotic Cardiovascular Disease - Sodium-Glucose Cotransporter-2 Inhibitors vs. Glucagon-Like Peptide-1 Receptor Agonists

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation.* 1999; 100:1134-346.
2. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. *Diabetes Care.* 1998; 21:1138-145.
3. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 1998; 339:229-34.

4. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med.* 2008; 358:580–91.
5. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia.* 2016; 59:2298–307.
6. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018; 41:2669-701.
7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015; 373(22):2117–128.
8. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al; VERTIS CV Investigators. Ertugliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2020; 383:1425-435.
9. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017; 377(7):644-57.
10. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2019; 380(4):347-57.
11. Zelniker TA, Wiviott SD, Raz I, Im K, Godrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet.* 2019; 393(10166):31-39.
12. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. *JAMA Cardiol.* 2021; 6:148-58.
13. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med.* 2019; 380:2295-306.
14. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med.* 2015; 373:2247-257.
15. Hernandez AF, Green JB, Janmohamed S, D'Agostino Sr RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet.* 2018; 392:1519-529.
16. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al; LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and

- cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2016; 375:311-22.
17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2016; 375:1834-844.
 18. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al; For the PIONEER6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2019; 381:841-51.
 19. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JP, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2017; 377:1228-239.
 20. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al; For the REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet.* 2019; 394:121-30.
 21. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet Diabetes Endocrinol.* 2019; 7:776-85.
 22. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation.* 2019; 139:2022-031.
 23. Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019; 7:834-44.
 24. Poonawalla I, Bowe A, Tindal M, Meah YA, Schwab P. Comparative effectiveness of SGLT2 inhibitors vs. GLP-1 agonists. *Diabetes* 2020; 69 (Suppl 1).
 25. Goncalves E, Bell DSH. Combination treatment of SGLT2 inhibitors and GLP-1 Receptor Agonists: Symbiotic effects on metabolism and cardiorenal risk. *Diabetes Ther.* 2018; 9:919-26.
 26. Frias JP, Guja C, Hardy E, Ahmed A, Dong F, Ohman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol.* 2016; 4:1004-016.
 27. Ludvik B, Frias JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol.* 2018; 6:370-381.
 28. Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL,

et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. *Cardiovasc Diabetol.* 2019; 18:138.

CHAPTER 20: SHOULD TYPE 2 DIABETES MELLITUS WITHOUT MICRO OR MACRO-VASCULAR COMPLICATION BE TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER TYPE 2

Type 2 diabetes mellitus patient without micro or macro vascular complication should be treated first with SGLT2

- Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al. DECLARE-TIMI 58: Participants' baseline characteristics. *Diabetes Obes Metab.* 2018; 20:1102-110.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. *Am Heart J.* 2018; 200:83-9.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2019; 380(4):347-57.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med.* 2017; 377:644-57.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med.* 2015; 373:2117-128.
- Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. *Diabetes Obes Metab.* 2013; 15(12):1154-160.
- Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care.* 2013; 36(12):4015-021.
- Thayer S, Aguilar R, Korror S, Chow W. HbA1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans. *Clin Ther.* 2017; 39(10):2061-072.
- Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. *Indian J Med Res.* 2007; 125(3):217-30.
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2019; 74(10):e177-e232.
- Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the

Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail.* 2019; 21(10):1169-186.

CHAPTER 21: METFORMIN IN HYPERGLYCEMIA IN PREGNANCY – YES

- American Diabetes Association Professional Practice Committee; 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2025. *Diabetes Care* 1 January 2025; 48 (Supplement_1): S306–S320. <https://doi.org/10.2337/dc25-S015>
 - Tarry-Adkins, J.L., Ozanne, S.E. & Aiken, C.E. Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. *Sci Rep* 11, 9240 (2021). <https://doi.org/10.1038/s41598-021-88650-5>
 - Paschou SA, Shalit A, Gerontiti E, Athanasiadou KI, Kalampokas T, Psaltopoulou T, Lambrinouadaki I, Anastasiou E, Wolffenbuttel BHR, Goulis DG. Efficacy and safety of metformin during pregnancy: an update. *Endocrine.* 2024 Feb;83(2):259-269. doi: 10.1007/s12020-023-03550-0.
- Metformin Should Not Be Prescribed in Case of Hyperglycemia in Pregnancy**
- American Diabetes Association. (2025). Standards of medical care in diabetes—2025. *Diabetes Care.* Retrieved from <https://diabetesjournals.org>
- Ekpebegh, C., Omotoso, B., & Motshoge, T. (2020). The impact of metformin on fetal neurodevelopment: A review of evidence. *Journal of Diabetes Research*, 2020, 1-10. <https://doi.org/10.1155/2020/3054539>
- Hanem, L. G. E., Salvesen, Ø., Juliusson, P. B., et al. (2019). In utero exposure to metformin and long-term metabolic risk in offspring. *Lancet Diabetes & Endocrinology*, 7(4), 278–285. [https://doi.org/10.1016/S2213-8587\(19\)30001-8](https://doi.org/10.1016/S2213-8587(19)30001-8)
- Kapadia, M., Shah, J. S., & Malhotra, S. (2017). Ethical concerns in the off-label use of metformin during pregnancy. *Ethics in Medicine*, 35(2), 123–131. <https://doi.org/10.1097/0000-0000-0000>
- Landstra, C. P., & Poston, L. (2021). Insulin therapy in the management of gestational diabetes. *Clinical Obstetrics and Gynecology*, 64(2), 291–302. <https://doi.org/10.1097/GRF.0000000000000642>
- McIntyre, H. D., Catalano, P., Zhang, C., et al. (2019). FIGO recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *International Journal of Gynecology & Obstetrics*, 144(3), 251–258. <https://doi.org/10.1002/ijgo.12749>
- Mottola, M. F., Giroux, I., Gratton, R., et al. (2018). Structured lifestyle interventions for managing gestational diabetes. *Journal of Maternal-Fetal Medicine*, 31(10), 1269–1277. <https://doi.org/10.1080/14767058.2017.1363734>
- Nankervis, A., Conn, J., & Cheung, N. W. (2021). Safety concerns with metformin use during pregnancy. *Diabetes & Metabolism Research Reviews*, 37(5), e3459. <https://doi.org/10.1002/dmrr.3459>
- Rowan, J. A., Hague, W. M., Gao, W., et al. (2008). MiG trial: Metformin versus insulin for the treatment of gestational diabetes. *New England Journal of Medicine*, 358(19), 2003–2015. <https://doi.org/10.1056/NEJMoa0707193>

Salomäki, H., Väänänen, T., & Ekblad, U. (2016). Pharmacokinetics of metformin during pregnancy. *European Journal of Clinical Pharmacology*, 72(6), 731–738. <https://doi.org/10.1007/s00228-016-2039-y>

Use of Metformin in Hyperglycemia During Pregnancy

1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. *Diabetes Care*. 2025;48(Supplement_1):S306–S320. <https://doi.org/10.2337/dc25-S015>
2. Rowan JA, Hague WM, Gao W, et al. MiG trial: Metformin versus insulin for the treatment of gestational diabetes. *New England Journal of Medicine*. 2008;358(19):2003–2015. <https://doi.org/10.1056/NEJMoa0707193>
3. Hanem LG, Salvesen Ø, Juliusson PB, et al. In utero exposure to metformin and long-term metabolic risk in offspring. *Lancet Diabetes & Endocrinology*. 2019;7(4):278–285. [https://doi.org/10.1016/S2213-8587\(19\)30001-8](https://doi.org/10.1016/S2213-8587(19)30001-8)
4. Tarry-Adkins JL, Ozanne SE, Aiken CE. Impact of metformin treatment during pregnancy on maternal outcomes: A systematic review/meta-analysis. *Scientific Reports*. 2021;11:9240. <https://doi.org/10.1038/s41598-021-88650-5>
5. Ekpebegh C, Omotoso B, Motshoge T. The impact of metformin on fetal neurodevelopment: A review of evidence. *Journal of Diabetes Research*. 2020;2020:3054539. <https://doi.org/10.1155/2020/3054539>
6. McIntyre HD, Catalano P, Zhang C, et al. FIGO recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *International Journal of Gy-*

necology & Obstetrics. 2019;144(3):251–258. <https://doi.org/10.1002/ijgo.12749>

CHAPTER 22: METFORMIN IS DRUG OF CHOICE WHEN TREATING PERSONS WITH PREDIABETES

1. Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, Dhandhanika VK, Bhansali A, Rao PV, Desai A, Kalra S, Gupta A, Lakshmy R, Madhu SV, Elangovan N, Chowdhury S, Venkatesan U, Subashini R, Kaur T, Dhaliwal RS, Mohan V; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol*. 2023 Jul;11(7):474–489. doi: 10.1016/S2213-8587(23)00119-5. Epub 2023 Jun 7. PMID: 37301218.
2. Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. *Annu Rev Public Health*. 2021 Apr 1;42:59–77. doi: 10.1146/annurev-publhealth-090419-102644. Epub 2021 Dec 23. PMID: 33355476; PMCID: PMC8026645.
3. Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, Han J. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. *Cancer Med*. 2018 Apr;7(4):1070–1080. doi: 10.1002/cam4.1354. Epub 2018 Feb 24. PMID: 29476615; PMCID: PMC5911601.
4. RSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. *Int J Diabetes Dev Ctries*. 2022 Oct;42(Suppl 1):1–143. doi: 10.1007/s13410-022-01129-5. Epub 2022 Oct 6. PMCID: PMC9534592.

GLP 1RA is Drug of Choice When Treating Persons With Prediabetes

1. Organization WH, Federation ID. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization.
2. Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. *Nutr Metab Cardiovasc Dis*. 2014;24:1317–22.
3. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389:1399–409.
4. Pratley RE, Jacob S, Baek S, Trautmann ME, Hompesch M, Han O, et al. Efficacy and safety of efglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. *BMJ Open Diabetes Res Care*. 2022;10: e002207.
5. Salamah, H.M., Marey, A., Abugdida, M. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetol Metab Syndr* 16, 129 (2024). <https://doi.org/10.1186/s13098-024-01371-3>

CHAPTER 23: CONTINUOUS GLUCOSE MONITORING SYSTEM FOR T2DM:

UNTAPPED POTENTIAL VERSUS HYPED-UP TOOL

CGMS for T2DM – A guide to improved glucose control – The NEED of the hour

1. Tan, Y.Y., Suan, E., Koh, G.C.H. et al. Effectiveness of continuous glucose monitoring in patient management of Type 2 Diabetes Mellitus: an umbrella review of systematic reviews from 2011 to 2024. *Arch Public Health* 82, 231 (2024). <https://doi.org/10.1186/s13690-024-01459-2>
2. Ajjan, R.A., Battelino, T., Cos, X. et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. *Nat Rev Endocrinol* 20, 426–440 (2024). <https://doi.org/10.1038/s41574-024-00973-1>
3. Klupa, Tomasz et al. “Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease.” *Diabetes therapy: research, treatment and education of diabetes and related disorders* vol. 14,8 (2023): 1241-1266. doi:10.1007/s13300-023-01431-3
4. Jackson MA, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. *Diabetes Technol Ther*. 2021 Mar;23(S1):S27-S34. doi: 10.1089/dia.2021.0007. PMID: 33534631; PMCID: PMC7957379.
5. RSSDI Expert Consensus for Optimal Glucose Monitoring in Diabetes Mellitus in India and Recommendations for Clinical Practice; Makkar et al; *International Journal of Clinical Metabolism and Diabetes*; DOI: 10.1177/30502071241293567
6. Kesavadev J, Misra A, Saboo B, et al. Time-in-range and frequency of contin-

uous glucose monitoring: recommendations for South Asia. *Diabetes Metab Syndr*. 2022;16(1):102345

7. Kesavadev J, Vigersky R, Shin J, et al. Assessing the therapeutic utility of professional continuous glucose monitoring in type 2 diabetes across various therapies: a retrospective evaluation. *Adv Ther*. 2017;34(8):1918-1927.

CHAPTER 24: AUTOMATED INSULIN DELIVERY FOR ALL PEOPLE WITH TYPE 1 DIABETES: YES

1. Zaharieva, D. P., Morrison, D., Paldus, B., Lal, R. A., Buckingham, B. A., & O'Neal, D. N. (2023). *Practical Aspects and Exercise Safety Benefits of Automated Insulin Delivery Systems in Type 1 Diabetes*. **Diabetes Spectrum**, 36(2), 127–133. <https://doi.org/10.2337/dsi22-0018>
2. Kesavadev, J., Krishnan, G., & Mohan, V. (2021). *Digital Health and Diabetes: Experience from India*. **Therapeutic Advances in Endocrinology and Metabolism**, 12, 1–13. <https://doi.org/10.1177/20420188211054676>
3. Bassi, M., Franzone, D., Dufour, F., Strati, M. F., Scalas, M., Tantari, G., Aloï, C., Salina, A., d'Annunzio, G., Maghnie, M., & Minuto, N. (2023). *Automated Insulin Delivery Systems: Use and Efficacy in Children and Adults with Type 1 Diabetes in Europe in Early 2023*. **Life**, 13(783). <https://doi.org/10.3390/life13030783>
4. Jayaraman, M., Bagga, G., & Thoke, S. (2021). *Management of Type 1 Diabetes Mellitus During the COVID-19 Pandemic*. **Medical Journal Armed Forces India**, 77(4), 455–460. <https://doi.org/10.1016/j.mjafi.2021.04.001>

5. Rimon, M. T. I., Hasan, M. W., Hassan, M. F., & Cesmeçi, S. (2024). *Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions*. **Pharmaceutics**, 16(944). <https://doi.org/10.3390/pharmaceutics16070944>
6. Oliver, N., Reddy, M., Marriott, C., Walker, T., & Heinemann, L. (2019). *Open Source Automated Insulin Delivery: Addressing the Challenge*. **NPJ Digital Medicine**, 2(124). <https://doi.org/10.1038/s41746-019-0202-1>

Automation in Insulin Delivery for all Type 1 Diabetes: NO

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513–1530
2. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. *BMJ* 2007;334:299
3. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403
4. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–1350

5. Ramchandani N, Heptulla RA. New technologies for diabetes: a review of the present and the future. *Int J Pediatr Endocrinol* 2012;2012:28
6. G. Alexander Fleming, John R. Petrie, Richard M. Bergenstal, Reinhard W. Holl, Anne L. Peters, Lutz Heinemann; Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. *Diabetes Care* 1 January 2020; 43(1): 250–260. <https://doi.org/10.2337/dci19-0062>
7. Markov AM, Krutilova P, Cedeno AE, McGill JB, McKee AM. Interruption of Continuous Glucose Monitoring: Frequency and Adverse Consequences. *J Diabetes Sci Technol*. 2024 Sep;18(5):1096-1101. doi: 10.1177/19322968231156572. Epub 2023 Feb 23. PMID: 36824046; PMCID: PMC11418458.
4. Shah, A., et al. (2020). Non-invasive markers for liver fibrosis: Utility in diabetes management. *Journal of Diabetes Research*, 2020, 1-9.
5. Liu, X., et al. (2019). Cost-effectiveness of non-invasive fibrosis markers in patients with type 2 diabetes. *Journal of Clinical Gastroenterology*, 53(6), 538-545.

FIB-4 Score in People with Diabetes: A Misleading Indicator for Liver Risk Assessment

CHAPTER 25: THE FIB-4 SCORE: A CRUCIAL TOOL FOR LIVER RISK ASSESSMENT IN DIABETIC PATIENTS

1. Kawata, N., et al. (2021). FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients. *Diabetology International*, 12(2), 118-125.
2. Kim, J., et al. (2024). Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis. *Diagnosics*, 14, 2500.
3. American Diabetes Association. (2022). Standards of medical care in diabetes—2022. *Diabetes Care*, 45(Supplement 1), S1-S2.
1. Kim RG, Deng J, Reaso JN, Grenert JP, Khalili M. Noninvasive Fibrosis Screening in Fatty Liver Disease Among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 Score Accuracy. *Diabetes Care*. 2022 Oct 1;45(10):2449-2451. doi: 10.2337/dc22-0556. PMID: 35947698; PMCID: PMC9643136.
2. Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. *JHEP Rep*. 2020 Jan 20;2(2):100067. doi: 10.1016/j.jhepr.2020.100067. PMID: 32118201; PMCID: PMC7047178.
3. Singh J, Ibrahim B, Jackson NJ, Khalil H, Valenzuela J, Yanny B, Saab S. Lower FIB-4 threshold in patients with diabetes improves diagnostic accuracy of the test in a Hispanic population. *Transl Gastroenterol Hepatol*. 2024 Mar 15;9:16. doi: 10.21037/tgh-23-62. PMID: 38716213; PMCID: PMC11074489.
4. Kim, J.; Ito, T.; Arai, T.; Atsukawa, M.; Kawanaka, M.; Toyoda, H.; Honda, T.; Yu, M.-L.; Yoon, E.L.; Jun, D.W.; et al. Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis.

Diagnostics 2024, 14, 2500. <https://doi.org/10.3390/diagnostics14222500>

FIB-4 Score in Diabetes

1. Kawata, N., et al. (2021). FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients. *Diabetology International*, 12(2), 118-125.
2. Kim, J., et al. (2024). Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis. *Diagnostics*, 14, 2500.
3. Kim RG, et al. (2022). Noninvasive Fibrosis Screening in Fatty Liver Disease Among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 Score Accuracy. *Diabetes Care*, 45(10), 2449-2451.
4. Patel K, Sebastiani G. (2020). Limitations of non-invasive tests for assessment of liver fibrosis. *JHEP Reports*, 2(2), 100067.